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A method is described for the identification of multi-subunit 
biocomplex drug targets. The method includes identifying a 
target that performs a biological function, wherein the target 
comprises one or more subunits, wherein a minimum num-
ber of the one or more subunits is inactivated to inhibit the 
biological function. The method includes selecting a drug 
that binds specifically to each subunit of the one or more 
subunits with a target probability. The method describes a 
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total number of the one or more subunits using a binomial 
distribution, wherein the inhibition efficiency comprises a 
probability that the delivered drug blocks the biological 
function. The method includes confirming empirically the 
relationship using an experimental target. The method 
includes administering the drug to the target to treat a 
multi-drug resistant disease, wherein the target comprises a 
biological complex in a mammalian subject. 
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C* Inhibition by inactive DNA (Z=1) 
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1 
METHOD FOR DESIGNING COMPOUNDS 
AND COMPOSITIONS USEFUL FOR 
TARGETING HIGH STOICHIOMETRIC 
COMPLEXES TO TREAT CONDITIONS, 
INCLUDING TREATMENT OF VIRUSES, 
BACTERIA, AND CANCERS HAVING 
ACQUIRED DRUG RESISTANCE 
This Application Is A§ 371 National State Application Of 
PCT/US2016/031292 Filed May 6, 2016 Which Claims 
Priority To U.S. Provisional Patent Application Ser. No. 
62/158,114, Filed May 7, 2015, The Entire Disclosure Of 
Which Are Incorporated By Reference In Their Entirety. 
GOVERNMENT INTEREST 
This invention was made with govermnent support under 
EB012135. EB003730, and CA151648 awarded by the 
National Institutes of Health. The govermnent has certain 
rights in the invention. 
All patents, patent applications and publications cited 
herein are hereby incorporated by reference in their entirety. 
The disclosures of these publications in their entireties are 
hereby incorporated by reference into this application in 
order to more fully describe the state of the art as known to 
those skilled therein as of the date of the invention described 
and claimed herein 
This patent disclosure contains material that is subject to 
copyright protection. The copyright owner has no objection 
to the facsimile reproduction by anyone of the patent docu-
ment or the patent disclosure as it appears in the U.S. Patent 
and Trademark Office patent file or records, but otherwise 
reserves any and all copyright rights. 
INTRODUCTION 
2 
tance of cancer has escalated and has partially contributed to 
the -600.000 deaths in the USA in 2012 [37]. HIV drug 
resistance has also become a major issue [38]. Many com-
mon pathogens have become resistant to current drug treat-
5 ments, with new infectious diseases on the rise. The use of 
multidrug-resistant agents in biological weapons has created 
a previously unrealized challenge [39]. Thus, there is a need 
to develop new treatment strategies to combat drug resis-
tance with new drug development methods. 
10 The first FDA-approved drug to treat multidrug-resistant 
tuberculosis, bedaquiline, follows a new mechanism of 
inhibiting the bacterial ATP synthase of M. tuberculosis and 
other mycobacterial species, but had little activity against 
15 
other bacteria [40]. To combat multidrug resistance in can-
cer, several approaches have been explored. One method is 
to target components that are highly important for the 
growth of the biological entity [41,42]. Another approach 
uses nano-drug delivery carriers that are expected to 
20 enhance the binding efficiency of drugs to cancer cells[43, 
44,45,46], or cocktail therapy [47]. A third approach is to 
develop new combinational drugs with higher potency by 
acting on multiple targets [48,49]. This involves identifying 
multiple targets that when treated leads to a synergetic effect 
25 and optimizing the design of multi-target ligands[50]. 
The approach of developing highly potent drugs through 
targeting protein or RNA complexes with high stoichiometry 
has never been reported due to challenges in comparing 
efficacies of two drugs that can be confused by target 
30 essentiality with binding affinity. For instance, if two drugs 
target two stoichiometrically different targets, it becomes 
extremely difficult to prove whether the difference in drug 
efficiency is due to differences in their target binding affinity 
or essential level in the growth of the biological organism. 
35 In order to quantify effects from targeting biocomplexes of 
different stoichiometry, a well-studied multicomponent sys-
tem is required that allows empirical comparison of func-
tional inhibition of individual components that are com-
Bacteria, viruses and cells contain biocomplexes and 
nanomachines composed of multiple subunits, such as bio-
motors [1,2,3,4], pumps [5], exosomes [6,7,8], valves [9,10, 
11], membrane pores [12,13,14,15], chaperonins[16], 40 
PCNA [17], ATPase [18,19], and tubes [20]. From a nano-
biotechnological standpoint, these nanomachines can be 
used and converted to build sophisticated nano-devices 
including molecular sensors [21,22,23], patterned arrays, 
actuators [24], chips, microelectromechanical systems 
(MEMS) [25], molecular sorters [26], single pore DNA 
sequencing apparatus [12,13,21,27] or other revolutionary 
electronic and optical devices [28,29]. From a pharmaceu-
tical standpoint, these multi-subunit biocomplexes or nano-
machines have a potential for use as drug targets for thera-
peutics, as well as diagnostic applications such as pathogen 
detection, disease diagnosis, drug delivery, and treatment of 
diseases [22,23,30,31]. In the ASCE (Additional Strand 
Catalytic E) family including the AAA+ (ATPases Associ-
ated with diverse cellular Activities) and the FtsK-HerA 
superfamily in bacteria, viruses and cells, there are nano-
motors that perform a wide range of functions [19,32,33] 
critical to chromosome segregation, bacterial binary fission, 
DNA/RNA and cell component transportation, membrane 
sorting, cellular reorganization, cell division, RNA transcrip- 60 
tion, as well as DNA replication, riding, repair, and recom-
bination [1,34,35,36]. One of the directions of NIH Road-
map is to utilize these cellular nanomachines and 
biocomplexes for biomedical applications. 
posed of different number of subunits. 
An example of one nanobiomachine is the dsDNA trans-
location motor, for which the ATPase protein is a pivotal 
component that assembles into a hexameric ring structure 
and translates the action of ATP binding and hydrolysis into 
mechanical motion to translocate DNA physically. The DNA 
45 packaging motor of bacteriophage phi29 (FIG. lA) [9,51, 
52,53] is composed of three essential co-axial rings: 1) a 
dodecameric connector ring located at the vertex of the viral 
procapsid; 2) a hexameric packaging RNA (pRNA) ring [52] 
bound to the N-terminus of the connector [54], and 3) a 
50 hexameric ring of ATPase gp 16 attached to the helical region 
of pRNA [10,19,55], powered through the hydrolysis of ATP 
resulting in DNA packaging. The use of Yang Hui's Triangle 
(FIG. lB) or binomial distribution to determine the stoichi-
ometry of the pRNA was first reported in 1997 [56]. The use 
55 of similar mathematical methods to determine the stoichi-
ometry of the protein subunits has also been reported more 
recently [51]. The copy number of ATP molecules required 
to package one full phi29 genomic dsDNA was predicted to 
be 10000 [57]. It has recently been shown that this hexam-
eric motor uses a revolution mechanism without rotation to 
translocate its genomic DNA [10,19,33,35,36,58,59]. 
Herein, the present inventors propose that the inhibitory 
efficiency of a drug is related to the stoichiometry of its 
targeted biocomplex; the higher the stoichiometry of the 
target complex, the more efficient the drug. This can lead to 
the development of potent therapeutics against high-stoi-
chiometric biomachines or biocomplexes as drug targets. 
Acquired drug resistance has become a major reason for 65 
failure treatment of a range of diseases, i.e., the chemo-
therapy for cancer, bacterial or viral infections. Drug resis-
US 10,975,412 B2 
3 4 
This method was employed as described herein by using 
a mutant subunit as the drugged inactive target to calculate 
the theoretical inhibition efficiency via binomial distribu-
tion, and compared with experimental data from a defined in 
vitro viral assembly system. Since biomotors share certain 5 
common structures and operation mechanisms [1,36,59,60], 
the approach in drug development reported here has general 
applications especially in developing new generations of 
drugs for combating the rising acquired drug resistance in 
viruses, bacteria, and cancers [38,61,62]. 10 
FIG. lC is an illustration ofZ=6 and K=l, drug targeting 
any one subunit of the complex will block its activity. 
FIG. lD is an AFM image of hexameric re-engineered 
pRNArings. 
FIG. lE is a 3D structure of hexameric pRNA ring top 
view and side view from the crystal structure of3WJ (PDB 
ID: pRNA 3WJ, 4KZ2). 
FIG. lF is a crystal hexameric structure of AAA+ Protein 
CbbX withtop view and side view [85] (PDB ID: CbbX, 
3Znh, http://www.ebi.ac.uk/pdbe/emdb/). 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
Disclosed herein is a method for designing compounds 
useful for treating conditions that can be treated by targeting 
high stoichiometric complexes, which is useful, for 
example, in designing drugs for against in viruses, bacteria, 
and cancers having acquired drug resistance. 
FIG. lG is a structure of the hexameric AAA+ molecular 
machine ClpC with adaptor protein MecA. [86] (PDB ID: 
MecA-ClpC, 3PXG). 
FIGS. 2A-2C show a theoretical plot (with variable Z) and 
15 empirical data illustrate inhibition efficiency with drug tar-
geting to genomic DNA (Z-1 ). 
FIG. 2A is a gel showing the phi29 genome DNA treated 
with endonuclease EcoRl. 
FIG. 2B is a plot of virion assembly derived from bino-
20 mial distribution equation 2, which showed that the DNA 
has stoichiometry of 1. 
As described herein, Phi29 DNA-packaging motor com-
ponents were used to test the method for use in connection 25 
with targets of different stoichiometries. Virion assembly 
efficiency was assayed with Yang Hui's Triangle: 
FIG. 2C is a viral assembly inhibition effect of mutant 
DNA as model of drugged component with Z=l, showing 
the linear relationship to p with low slope. 
FIGS. 3A-3C is a theoretical plot (K=l to 6) and empirical 
data to illustrate inhibition efficiency with drug targeting 
pRNA (Z=6). 
where Z=stoichiometry, M=drugged subunits in each bio-
complex, p and q represent the fraction of drugged and 
non-drugged subunits in the population. 
As reported herein, inhibition efficiency follows a power 
function. When number of drugged subunits to block the 
function of the biocomplex K=l, the fraction of uninhibited 
biocomplex equals q2 • Thus, stoichiometry has a multipli-
cative effect on inhibition. Tested targets with a thousand 
subunits showed the highest inhibition effect, followed by 
those with six and a single subunit. Complete inhibition of 
virus replication was found when Z=6. 
As disclosed herein, drug inhibition potency depends on 
the stoichiometry of the targeted components of the bio-
complex or nano-machine. The inhibition effect follows a 
power function of the stoichiometry of the target biocom-
plex. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The features of the invention are set forth with particu-
larity in the appended claims. A better understanding of the 
features and advantages of the present invention will be 
obtained by reference to the following detailed description 
that sets forth illustrative embodiments, in which the prin-
ciples of the invention are used, and the accompanying 
drawings of which: 
FIGS. lA-lF show the stoichiometry of viral DNA pack-
aging motor 
FIG. lA is an Illustration of Phi29 DNA packaging motor 
composed of 1 copy of genomic DNA that revolves through 
the channel wall (left panel), 6 copies of pRNA, 6 copies of 
ATPase gp16 and a connector channel. 
FIG. 1B is a Yang Hui Triangle. 
FIG. 3A is the sequence and secondary structure of 
wild-type pRNA of phi29 DNA packaging motor (upper 
30 panel) and inactive mutant pRNA with 4 bases mutation at 
5'end of the DNA translocation domain serving as a model 
of drugged inactive pRNA (lower panel). 
FIG. 3B is a fitting the phage assembly inhibition result by 
inactive mutant pRNA with the theoretical plots derived 
35 from Equation 2 matched with Z=6 and K=l. 
FIG. 3C compares the viral assembly inhibition effect by 
drugged pRNA at different concentration with the 
undrugged pRNA with same dilution factor. 
FIGS. 4A-4B shows complete inhibition of viral assembly 
40 in vivo by mutant pRNA as a model of drugged complex 
(Z=6). 
FIG. 4A shows inactivation of pRNA by introducing a 
4-nucleotide mutation at the 3'end. 
FIG. 4B shows virion production by wild-type phi29 
45 infection using host cell B. subtilis harboring plasmid 
expressing mutant pRNA, wild-type pRNA, or plasmid only. 
FIGS. SA-SC show comparison of inhibition efficiency 
using targets with different Z values. 
FIG. SA shows virion production inhibition effect of 
50 mutant gp16 (Z=6) at different concentration. 
FIG. SB shows inhibition efficiency by y-s-ATP with ATP 
with high Z value. 
FIG. SC compares the virus assembly inhibition effect by 
drugged components of DNA, pRNA, gp16 and ATP with 
55 stoichiometry of 1, 6, 6, 10000 respectively. 
60 
FIG. 6 shows a relationship between stoichiometry (Z) 
and drug targeting level (a combined result of drug binding 
efficacy and drug concentration) to reach the inhibition 
effect (IC). 
FIGS. 7A-7C show the morphology and stoichiometry of 
Phi29 DNA packaging motor. 
FIG. 7A illustrates a Phi29 DNA packaging motor com-
posed of 1 copy of genomic DNA through a channel 
composed of three coaxil rings, a 12 subunit connector, 6 
65 subunit pRNA, 6 subunit ATPase gp16. 
FIG. 7B shows a binomial distribution equation with its 
coefficient displayed by Yang Hui Triangle. 
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FIG. 7C shows an illustration of Z=6 and K=l, drug 
targeting any subunit of a hexameric complex in blocking its 
function. 
FIG. 8 shows the relationship between the stoichiometry 
of homomeric target complex (Z) and target complex inhi- 5 
bition effect (IC). 
FIG. 9 compares Phi29 viral assembly inhibition effi-
ciency by targeting components of the system with different 
stoichiometries (left panel), DNA with stoichiometry of 1, 
ATPase gp16 with stoichiometry of 6 (right upper panel), 10 
pRNA with stoichiometry of 6 (right lower panel), and ATP 
with stoichiometry of 10,000. Adapted from ref. [13] with 
permission. 
FIGS. lOA-lOD shows widespread biomotors or nano-
machines that are composed of multisubunit complex. 
FIG. lOA shows rotation nanomachine DnaB helicase 
which is a hexamer [69] (PDB ID: 4ESV). 
15 
6 
FIG. 13C is a viral assembly inhibition effect of mutant 
DNA as model of drugged component with Z=l, showing 
the linear relationship to p with low slope. 
FIGS. 14A-14C is a theoretical plot (K=l to 6) and 
empirical data to illustrate inhibition efficiency with drug 
targeting pRNA (Z=6). 
FIG. 14A is the sequence and secondary structure of 
wild-type pRNA of phi29 DNA packaging motor (upper 
panel) and inactive mutant pRNA with 4 bases mutation at 
5' end of the DNA translocation domain serving as a model 
of drugged inactive pRNA (lower panel). 
FIG. 14B is a fitting the phage assembly inhibition result 
by inactive mutant pRNA with the theoretical plots derived 
from Equation 2 matched with Z=6 and K=l. 
FIG. 14C compares the viral assembly inhibition effect by 
drugged pRNA at different concentration with the 
undrugged pRNA with same dilution factor. 
FIG. 10B shows rotation nanomachine RecA motor pro-
tein which is a hexamer [72] (PDB ID: 1N03). 
FIG. lOC shows revolution Phi29 DNA packaging motor 
which contains a hexameric pRNA [58]. 
FIGS. lSA-15B shows complete inhibition of viral 
assembly in vivo by mutant pRNA as a model of drugged 
20 complex (Z=6). 
FIG. 15A shows inactivation of pRNA by introducing a 
4-nucleotide mutation at the 3'end. FIG. lOD shows revolution DNA motor protein FtsK 
which is a hexamer [87] (PDB ID: 2IUU). 
FIGS. llA-llD show examples ofhomomeric multisub-
unit complex as drug target for developing potent drugs. 
FIG. 15B shows virion production by wild-type phi29 
infection using host cell B. subtilis harboring plasmid 
25 expressing mutant pRNA, wild-type pRNA, or plasmid only. 
FIG. llA shows tetrameric bpFabI. Tetrameric bpFabiis a 
key enzyme in fatty acid synthesis in bacterial, inhibitor 
PT155 forms a tetrameric complex with BpmFabI [31] 
(PDB ID: 4BKU). 
FIG. 11B shows inosine monophosphate dehydrogenase 30 
(IMPDH) [32] (PDB ID: 1AK5). Inosine monophosphate 
dehydrogenase is a key enzyme in guanine nucleotide bio-
synthesis pathway, inhibitors have been developed targeting 
the tetrameric IMPDH. 
FIG. llC shows a bacterial multidrug efflux transporter 35 
AcrB which forming a homotrimer[91](PDB ID: 11 WG). 
FIG. llD shows a multidrug exporter MexB from 
Pseudomonas aeruginosa forming a homotrimer[92] (PDB 
ID: 2V50). 
FIGS. 12A-12F show the stoichiometry of viral DNA 40 
packaging motor 
FIGS. 16A-16C show comparison of inhibition efficiency 
using targets with different Z values. 
FIG. 16A shows virion production inhibition effect of 
mutant gp16 (Z=6) at different concentration. 
FIG. 16B shows inhibition efficiency by y-s-ATP with 
ATP with high Z value. 
FIG.16C compares the virus assembly inhibition effect by 
drugged components of DNA, pRNA, gp16 and ATP with 
stoichiometry of 1, 6, 6, 10000 respectively. 
FIG. 17 shows a relationship between stoichiometry (Z) 
and drug targeting level (a combined result of drug binding 
efficacy and drug concentration) to reach the inhibition 
effect (IC). 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The disclosure below includes Section 1 (which includes 
the Introduction set forth above and description of FIGS. 
FIG. 12A is an Illustration of Phi29 DNA packaging 
motor composed of 1 copy of genomic DNA that revolves 
through the channel wall (left panel), 6 copies of pRNA, 6 
copies of ATPase gp16 and a connector channel. 
FIG. 12B is a Yang Hui Triangle. 
FIG. 12C is an illustration of Z=6 and K=l, drug targeting 
any one subunit of the complex will block its activity. 
45 1-6), Section 2 (which includes description of FIGS. 7-11 set 
forth above), and Section 3 (which includes the description 
of FIGS. 12-17 set forth above). Each section discloses 
systems, devices, and methods for designing compounds 
FIG. 12D is an AFM image of hexameric re-engineered 
pRNArings. 
FIG. 12E is a 3D structure of hexameric pRNA ring top 
view and side view from the crystal structure of3WJ (PDB 
ID: pRNA 3WJ, 4KZ2). 
50 
FIG. 12F is a crystal hexameric structure of AAA+ 
Protein CbbX with op view and side view (PDB ID: CbbX, 55 
3Zuh, http://www.ebi.ac.uk/pdbe/emdb/). 
FIG. 12G is a structure of the hexameric AAA+ molecular 
machine ClpC with adaptor protein MecA. (PDB ID: MecA-
ClpC, 3PXG). 
FIGS. 13A-13C show a theoretical plot (with variable Z) 60 
and empirical data to illustrate inhibition efficiency with 
drug targeting to genomic DNA (Z-1 ). 
FIG. 13A is a gel showing the phi29 genome DNA treated 
with endonuclease EcoRl. 
FIG. 13B is a plot of virion assembly derived from 65 
binomial distribution equation 2, which showed that the 
DNA has stoichiometry of 1. 
and compositions as further described below. 
Section 1 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
The presently-disclosed subject matter includes a method 
for designing a compound or composition for treatment of 
virus, bacteria, or cancer having acquired drug resistance, 
which involves identifying a multi-subunit bio complex of 
the virus or bacteria that is distinct from other biocomplexes 
in the subject species, or selecting a multi-subunit bio 
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complex of the cancer containing a mutation; and designing 
a drug to target subunit of the biocomplex. The present 
inventors have surprisingly determined that the inhibitory 
efficiency of a drug is related to the stoichiometry of its 
targeted biocomplex; the higher the stoichiometry of the 5 
target complex, the more efficient the drug. 
This can lead to the development of potent therapeutics 
against high-stoichiometric biomachines or biocomplexes as 
drug targets. This method was employed as described herein 
by using a mutant subunit as the drugged inactive target to 10 
calculate the theoretical inhibition efficiency via binomial 
distribution, and compared with experimental data from a 
defined in vitro viral assembly system. 
The approach in drug development reported here has 
general applications especially in developing new genera- 15 
tions of drugs for combating the rising acquired drug resis-
tance in viruses, bacteria, and cancers. 
Disclosed herein is a method for designing compounds 
useful for treating conditions that can be treated by targeting 
high stoichiometric complexes, which is useful, for 20 
example, in designing drugs for against in viruses, bacteria, 
and cancers having acquired drug resistance. 
8 
embodiment, the manmialian subject is administered the 
drug identified or designed according to the methods of the 
invention. 
In one embodiment, methods are provided for increasing 
inhibition efficiency of a multimeric biocomplex. In one 
embodiment, the method comprises (a) identifying a target 
that performs a biological function, wherein the target 
comprises one or more subunits, wherein a minimum num-
ber of the one or more subunits is inactivated to inhibit the 
biological function; (b) selecting a drug that binds specifi-
cally to each subunit of the one or more subunits with a 
target probability, wherein the target probability comprises a 
common probability for each subunit that the drug delivered 
to the target inactivates the subunit; (c) describing a rela-
tionship between inhibition efficiency of the drug and total 
number of the one or more subunits using a binomial 
distribution, wherein the inhibition efficiency comprises a 
probability that the delivered drug blocks the biological 
function, wherein the inhibition efficiency is computed with 
respect to the minimum number and the total number; ( d) 
confirming empirically the relationship using an experimen-
tal target, wherein the target includes the experimental 
target; and ( e) contacting the drug to the target to treat a 
multi-drug resistant disease, wherein the target comprises a 
25 biological complex in a manmialian subject. In a further 
embodiment, the manmialian subject is administered the 
drug identified or designed according to the methods of the 
invention. 
where Z=stoichiometry, M=drugged subunits in each bio-
complex, p and q represent the fraction of drugged and 
non-drugged subunits in the population. 
Disclosed herein are methods for designing and/or iden-
tifying compounds useful for treating conditions that can be 
treated by targeting high stoichiometric complexes, which is 
useful, for example, in designing and/or identifying drugs 
for/against viruses, bacteria, and cancers having acquired 
drug resistance. In some embodiments, the compounds 
designed or identified herein may be an antibody, an anti-
sense oligonucleotide, miRNA, a short hairpin RNA, a small 
peptide, and the like directed to a component or subunit of 
the nanomachines (e.g., biomotors or biocomplexes) con-
templated herein. Other agents that could be used to bind the 
target compound include: protein, aptamer, LNA, chemical 
compounds and Polysaccharide. 
In one embodiment, methods are provided for optimizing 
30 biocomplex stoichiometry-based drug development. In one 
embodiment, the method comprises (a) identifying a target 
that performs a biological function, wherein the target 
comprises one or more subunits, wherein a minimum num-
ber of the one or more subunits is inactivated to inhibit the 
35 biological function; (b) selecting a drug that binds specifi-
cally to each subunit of the one or more subunits with a 
target probability, wherein the target probability comprises a 
common probability for each subunit that the drug delivered 
to the target inactivates the subunit; (c) describing a rela-
40 tionship between inhibition efficiency of the drug and total 
number of the one or more subunits using a binomial 
distribution, wherein the inhibition efficiency comprises a 
probability that the delivered drug blocks the biological 
function, wherein the inhibition efficiency is computed with 
45 respect to the minimum number and the total number; ( d) 
confirming empirically the relationship using an experimen-
tal target, wherein the target includes the experimental 
target; and ( e) contacting the drug to the target to treat a 
multi-drug resistant disease, wherein the target comprises a 
In one embodiment, methods are provided for the iden-
tification of multi-subunit biocomplex drug targets. In one 
embodiment, the method comprises (a) identifying a target 
that performs a biological function, wherein the target 
comprises one or more subunits, wherein a minimum num-
ber of the one or more subunits is inactivated to inhibit the 
biological function; (b) selecting a drug that binds specifi-
cally to each subunit of the one or more subunits with a 
target probability, wherein the target probability comprises a 
common probability for each subunit that the drug delivered 55 
to the target inactivates the subunit; (c) describing a rela-
tionship between inhibition efficiency of the drug and total 
number of the one or more subunits using a binomial 
distribution, wherein the inhibition efficiency comprises a 
probability that the delivered drug blocks the biological 60 
function, wherein the inhibition efficiency is computed with 
respect to the minimum number and the total number; ( d) 
confirming empirically the relationship using an experimen-
50 biological complex in a manmialian subject. In a further 
embodiment, the manmialian subject is administered the 
drug identified or designed according to the methods of the 
invention. 
In one embodiment, methods are provided for targeting a 
high stoichiometry biocomplex to increase drug targeting 
efficiency. In one embodiment, the method comprises (a) 
identifying a target that performs a biological function, 
wherein the target comprises one or more subunits, wherein 
a minimum number of the one or more subunits is inacti-
vated to inhibit the biological function; (b) selecting a drug 
that binds specifically to each subunit of the one or more 
subunits with a target probability, wherein the target prob-
ability comprises a common probability for each subunit that 
the drug delivered to the target inactivates the subunit; ( c) tal target, wherein the target includes the experimental 
target; and ( e) contacting the drug to the target to treat a 65 
multi-drug resistant disease, wherein the target comprises a 
biological complex in a manmialian subject. In a further 
describing a relationship between inhibition efficiency of the 
drug and total number of the one or more subunits using a 
binomial distribution, wherein the inhibition efficiency com-
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prises a probability that the delivered drug blocks the 
biological function, wherein the inhibition efficiency is 
computed with respect to the minimum number and the total 
number; ( d) confirming empirically the relationship using an 
experimental target, wherein the target includes the experi-
mental target; and ( e) contacting the drug to the target to 
treat a multi-drug resistant disease, wherein the target com-
prises a biological complex in a mammalian subject. In a 
further embodiment, the mammalian subject is administered 
the drug identified or designed according to the methods of 
the invention. 
In one embodiment, methods are provided for treating a 
subject afflicted with a multi-drug resistant disease. In one 
embodiment, the method comprises: (a) identifying a target 
that performs a biological function, wherein the target 
comprises one or more subunits, wherein a minimum num-
ber of the one or more subunits is inactivated to inhibit the 
biological function; (b) selecting a drug that binds specifi-
cally to each subunit of the one or more subunits with a 
target probability, wherein the target probability comprises a 
common probability for each subunit that the drug delivered 
to the target inactivates the subunit; (c) describing a rela-
tionship between inhibition efficiency of the drug and total 
number of the one or more subunits using a binomial 
distribution, wherein the inhibition efficiency comprises a 
probability that the delivered drug blocks the biological 
function, wherein the inhibition efficiency is computed with 
respect to the minimum number and the total number; ( d) 
confirming empirically the relationship using an experimen-
tal target, wherein the target includes the experimental 
target; and ( e) contacting the drug with the target to treat a 
multi-drug resistant disease, wherein the target comprises a 
biological complex in a mammalian subject. In a further 
embodiment, the mammalian subject is administered the 
drug identified or designed according to the methods of the 
invention. 
In some embodiments of the invention, the experimental 
target comprises a component or subunit of a multimeric 
biocomplex. Non-limiting examples of a multimeric bio-
complex include a receptor, a channel, an enzyme, and a 
transporter. In other embodiments, the experimental target 
comprises a component or subunit of a biological nanomo-
tor. Non-limiting examples of a biological nanomotor 
include a linear motor, a rotation motor, and a revolution 
motor. In further embodiments, the biological nanomotor 
further comprises an ATPase component. In some embodi-
ments, the biological nanomotor is a bacteriophage Phi29 
DNA packaging motor. As discussed herein, the bacterio-
phage Phi29 DNA packaging motor comprises a genomic 
dsDNA component, a packaging RNA component, an 
ATPase gp 16 component, an ATP component, or a combi-
nation thereof. 
In one embodiment, the biological motor or multimeric 
biocomplex is homomeric. In another embodiment, the 
biological motor or the multimeric biocomplex comprises a 
dimer, a hetero-oligomer, or a homo-oligomer. In some 
embodiments, the number of components or subunits com-
prising the biological motor or multimeric biocomplex is at 
least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 
or 100. In some embodiments, the number of components or 
subunits comprising the biological motor or multimeric 
biocomplex is at least 100, 200, 300, 400, 500, 600, 700, 
800,900, 1000,2000, 3000, 4000, 5000, 6000, 7000, 8000, 
9000, or 10,000. In some embodiments, the number of 
components or subunits comprising the biological motor or 
multimeric biocomplex is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
or 12. For example, the bacteriophage Phi29 DNA packag-
10 
ing motor comprises 1 copy of genomic dsDNA, and such 
copy comprises a subunit (e.g., 1 target subunit). For 
example, the bacteriophage Phi29 DNA packaging motor 
comprises 6 copies of packaging RNA, and such copies 
5 comprise subunits (e.g., 6 target subunits). For example, the 
bacteriophage Phi29 DNA packaging motor comprises 6 
copies of gp16, and such copies comprise subunits (e.g., 6 
target subunits). For example, the bacteriophage Phi29 DNA 
packaging motor comprises 10,000 copies of ATP, and such 
10 copies comprise subunits (e.g., 10.000 target subunits). 
As used herein and as is well understood in the art, 
"treatment" is an approach for obtaining beneficial or 
desired results, including clinical results. Beneficial or 
desired clinical results can include, but are not limited to, 
15 alleviation or amelioration of one or more symptoms or 
conditions, diminution of extent of disease, a stabilized (i.e., 
not worsening) state of disease, preventing spread of dis-
ease, delay or slowing of disease progression, amelioration 
or palliation of the disease state and remission (whether 
20 partial or total), whether detectable or undetectable. "Treat-
ment" can also refer to prolonging survival as compared to 
expected survival if not receiving treatment. 
The term "in need thereof' refers to the need for symp-
tomatic or asymptomatic relief from a condition associated 
25 with multi-drug resistance, such as, for example, a cancer, 
and/or a condition associated with a multi-drug resistant 
disease caused by a multidrug-resistant organism. The sub-
ject in need thereof may or may not be undergoing treatment 
for conditions related to, for example, a cancer, and/or a 
30 condition associated with a multi-drug resistant disease 
caused by a multidrug-resistant organism. In some embodi-
ments, the subject is a mammalian subject. In some embodi-
ments, the mammalian subject is a human, a dog, a cat, a 
bird, a pig, a horse, or a cow. In certain embodiments, the 
35 mammalian subject is a human. 
A multi-drug resistant disease can be caused by a multi-
drug-resistant organism. The multidrug resistant organism is 
no longer responsive to an antibiotic composition treatment, 
an antifungal composition treatment, an antiviral composi-
40 tion treatment, or an antiparasitic composition treatment. In 
one embodiment, the multidrug-resistant organism is a bac-
terium, a fungus, a virus, or a parasite. Non-limiting 
examples of a multidrug-resistant bacterium include a spe-
cies of staphylococcus, a species of enterococcus, a species 
45 of gonococcus, a species of streptococcus, a species of 
acinetobacter, a species of enterobacter, a species of kleb-
siella, a species of salmonella, a species of escherichia, a 
species of pseudomonas, and a species of mycobacterium. 
Non-limiting examples of a multidrug-resistant fungus 
50 include a species of candida and a species of scedosporium. 
Non-limiting examples of a multidrug-resistant virus 
include HIV, influenza, cytomegalovirus and herpes simplex 
virus. Non-limiting examples of a multidrug-resistant para-
site include a species of plasmodium, a species of toxo-
55 plasma, and a species of ascaris. 
The present disclosure relates generally to small molecule 
therapeutics useful the treatment of a multi-drug resistant 
cancer or a multi-drug resistant disease caused by a multi-
drug-resistant organism. In one embodiment, a drug identi-
60 fled or designed according to the methods described herein 
is administered to a subject to prevent or treat diseases or 
disorders associated with a multi-drug resistant cancer or a 
multi-drug resistant disease caused by a multidrug-resistant 
organism. In one embodiment, an effective amount of the 
65 drug identified or designed according to the methods 
described herein is administered to the subject. In some 
embodiments, the drug identified or designed according to 
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the methods described herein comprises a pharmaceutical 
composition administered to a subject in a pharmaceutically 
acceptable carrier. In some embodiments, the drug identified 
or designed according to the methods described herein can 
serve as a therapeutic method for the treatment of a multi- 5 
drug resistant cancer or a multi-drug resistant disease caused 
by a multidrug-resistant organism. 
12 
into the compositions. For oligonucleotide compounds, 
examples of pharmaceutically acceptable salts and their uses 
are further described in U.S. Pat. No. 6,287,860, which is 
hereby incorporated by reference in its entirety. 
Embodiments of the present invention can be adminis-
tered alone, or can be administered in a therapeutic cocktail 
or as a pharmaceutical composition. For example, a phar-
maceutical composition can comprise embodiments of the 
present invention, and a saline solution that includes a 
Embodiments of the invention may be used to treat a 
multi-drug resistant cancer or a multi-drug resistant disease 
caused by a multidrug-resistant organism Non-limiting 
examples of diseases, disorders, and/or illnesses which may 
benefit from embodiments of the present invention may 
include illnesses caused by Vancomycin-Resistant Entero-
cocci, tuberculosis, pneumonia, illnesses caused by Methi-
cillin-Resistant Staphylococcus aureus, cancer, food poison-
ing, legionnaire's disease, yeast infections, malaria, and 
helminthiasis. 
10 phosphate buffer. Embodiments of the present invention can 
be administered using the means and doses described herein. 
Embodiments of the present invention can be administered 
in combination with a suitable carrier. In one embodiment, 
the drug identified or designed according to the methods 
15 described herein encompass any pharmaceutically accept-
able salts, esters, or salts of such esters, or any other 
compound which, upon administration to a subject, provides 
(directly or indirectly) the biologically active metabolite or 
residue thereof. 
The drug identified or designed according to the methods 
described herein can be utilized in pharmaceutical compo-
sitions by adding an effective amount of a compound to a 20 
suitable pharmaceutically acceptable diluent or carrier. Use 
of the drug compounds and methods of the invention may 
also be useful prophylactically. 
An "effective amount". "sufficient amount" or "therapeu-
tically effective amount" as used herein is an amount of a 25 
composition that is sufficient to effect beneficial or desired 
results, including clinical results. As such, the effective 
amount may be sufficient, for example, to reduce or ame-
liorate the severity and/or duration of an affliction or con-
dition, or one or more symptoms thereof, prevent the 30 
advancement of conditions related to an affliction or condi-
A pharmaceutical composition of the invention is formu-
lated to be compatible with its intended route of adminis-
tration. Examples of routes of administration include par-
enteral, ( e.g., intravenous), intradermal, subcutaneous, oral 
( e.g., inhalation), transdermal (topical), transmucosal, and 
rectal administration. Solutions or suspensions used for 
parenteral, intradermal, or subcutaneous application can 
include the following components: a sterile diluent such as 
water for injection, saline solution, fixed oils, polyethylene 
glycols, glycerine, propylene glycol or other synthetic sol-
vents; antibacterial agents such as benzyl alcohol or methyl 
parabens; antioxidants such as ascorbic acid or sodium 
bisulfite; chelating agents such as ethylenediaminetet-
raacetic acid; buffers such as acetates, citrates or phosphates 
and agents for the adjustment of tonicity such as sodium 
tion, prevent the recurrence, development, or onset of one or 
more symptoms associated with an affliction or condition, or 
enhance or otherwise improve the prophylactic or therapeu-
tic effect(s) of another therapy. An effective amount also 
includes the amount of the composition that avoids or 
substantially attenuates undesirable side effects. 
The term "carrier" refers to a diluent, adjuvant, excipient, 
35 chloride or dextrose. pH can be adjusted with acids or bases, 
such as hydrochloric acid or sodium hydroxide. The paren-
teral preparation can be enclosed in ampoules, disposable 
syringes or multiple dose vials made of glass or plastic. 
Pharmaceutical compositions suitable for injectable use or vehicle with which a compound is administered. Non-
limiting examples of such pharmaceutical carriers include 
liquids, such as water and oils, including those of petroleum, 
animal, vegetable or synthetic origin, such as peanut oil, 
soybean oil, mineral oil, sesame oil and the like. The 
pharmaceutical carriers may also be saline, gum acacia, 
gelatin, starch paste, talc, keratin, colloidal silica, urea, and 
the like. In addition, auxiliary, stabilizing, thickening, lubri-
cating and coloring agents may be used. Other examples of 
suitable pharmaceutical carriers are described in Remington: 
40 include sterile aqueous solutions (where water soluble) or 
dispersions and sterile powders for the extemporaneous 
preparation of sterile injectable solutions or dispersions. For 
intravenous administration, suitable carriers include physi-
ological saline, bacteriostatic water, Cremophor EM™ 
45 (BASF, Parsippany. N.J.) or phosphate buffered saline 
(PBS). In all cases, the composition must be sterile and 
should be fluid to the extent that easy syringability exists. It 
must be stable under the conditions of manufacture and 
The Science and Practice of Pharmacy, 21st Edition (Uni-
versity of the Sciences in Philadelphia, ed., Lippincott 50 
Williams & Wilkins 2005); and Handbook of Pharmaceuti-
cal Excipients, 7th Edition (Raymond Rowe et al., ed., 
Pharmaceutical Press 2012); each hereby incorporated by 
reference in its entirety. 
The term "pharmaceutically acceptable salts" refers to 55 
physiologically and pharmaceutically acceptable salts of the 
compounds of the invention: i.e., salts that retain the desired 
biological activity of the parent compound and do not impart 
undesired toxicological effects thereto. A pharmaceutically 
acceptable carrier can comprise any and all solvents, dis- 60 
persion media, coatings, antibacterial and antifungal agents, 
isotonic and absorption delaying agents, and the like, com-
patible with pharmaceutical administration. The use of such 
media and agents for pharmaceutically active substances is 
well known in the art. Any conventional media or agent that 65 
is compatible with the active compound can be used. 
Supplementary active compounds can also be incorporated 
storage and must be preserved against the contaminating 
action of microorganisms such as bacteria and fungi. The 
carrier can be a solvent or dispersion medium containing, for 
example, water, ethanol, a pharmaceutically acceptable 
polyol like glycerol, propylene glycol, liquid polyetheylene 
glycol, and suitable mixtures thereof. The proper fluidity can 
be maintained, for example, by the use of a coating such as 
lecithin, by the maintenance of the required particle size in 
the case of dispersion and by the use of surfactants. Pre-
vention of the action of microorganisms can be achieved by 
various antibacterial and antifungal agents, for example, 
parabens, chlorobutanol, phenol, ascorbic acid, and thime-
rosal. In many cases, it can be useful to include isotonic 
agents, for example, sugars, polyalcohols such as mannitol, 
sorbitol, sodium chloride in the composition. Prolonged 
absorption of the injectable compositions can be brought 
about by including in the composition an agent which delays 
absorption, for example, aluminum monostearate and gela-
tin. 
US 10,975,412 B2 
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Sterile injectable solutions can be prepared by incorpo-
rating the compound in the required amount in an appropri-
14 
ate solvent with one or a combination of ingredients enu-
merated herein, as required, followed by filtered 
sterilization. Generally, dispersions are prepared by incor- 5 
porating the active compound into a sterile vehicle which 
contains a basic dispersion medium and the required other 
ingredients from those enumerated herein. In the case of 
sterile powders for the preparation of sterile injectable 
solutions, examples of useful preparation methods are 10 
vacuum drying and freeze-drying which yields a powder of 
the active ingredient plus any additional desired ingredient 
from a previously sterile-filtered solution thereof. 
the skill of those in the art. Dosing is dependent on severity 
and responsiveness of the disease state to be treated, with the 
course of treatment lasting from several days to several 
months, or until a cure is effected or a diminution of the 
disease state is achieved. Optimal dosing schedules can be 
calculated from measurements of drug accumulation in the 
body of the patient. Persons of ordinary skill can easily 
determine optimum dosages, dosing methodologies and 
repetition rates. Optimum dosages may vary depending on 
the relative potency of the drug identified or designed 
according to the methods described herein, and can gener-
ally be estimated based on EC50s found to be effective in in 
vitro and in vivo animal models. In some embodiments, the 
therapeutically effective amount is at least about 0.1 mg/kg 
body weight, at least about 0.25 mg/kg body weight, at least 
about 0.5 mg/kg body weight, at least about 0.75 mg/kg 
Oral compositions generally include an inert diluent or an 
edible carrier. They can be enclosed in gelatin capsules or 15 
compressed into tablets. For the purpose of oral therapeutic 
administration, the active compound can be incorporated 
with excipients and used in the form of tablets, troches, or 
capsules. Oral compositions can also be prepared using a 
fluid carrier for use as a mouthwash, wherein the compound 20 
in the fluid carrier is applied orally and swished and expec-
torated or swallowed. 
body weight, at least about 1 mg/kg body weight, at least 
about 2 mg/kg body weight, at least about 3 mg/kg body 
weight, at least about 4 mg/kg body weight, at least about 5 
mg/kg body weight, at least about 6 mg/kg body weight, at 
least about 7 mg/kg body weight, at least about 8 mg/kg 
body weight, at least about 9 mg/kg body weight, at least 
about 10 mg/kg body weight, at least about 15 mg/kg body 
weight, at least about 20 mg/kg body weight, at least about 
Pharmaceutically compatible binding agents, and/or adju-
vant materials can be included as part of the composition. 
The tablets, pills, capsules, troches and the like can contain 
any of the following ingredients, or compounds of a similar 
nature: a binder such as microcrystalline cellulose, gum 
tragacanth or gelatin; an excipient such as starch or Lactose, 
a disintegrating agent such as alginic acid, Primogel, or corn 
starch; a lubricant such as magnesium stearate or sterotes; a 
glidant such as colloidal silicon dioxide; a sweetening agent 
such as sucrose or saccharin; or a flavoring agent such as 
peppermint, methyl salicylate, or orange flavoring. 
Systemic administration can also be by transmucosal or 
transdermal means. For transmucosal or transdermal admin-
istration, penetrants appropriate to the harrier to be perme-
ated are used in the formulation. Such penetrants are gen-
erally known in the art, and include, for example, for 
transmucosal administration, detergents, bile salts, and 
fusidic acid derivatives. Transmucosal administration can be 
accomplished through the use of nasal sprays or supposito-
ries. For transdermal administration, the active compounds 
are formulated into ointments, salves, gels, or creams as 
generally known in the art. 
Formulations useful for topical administration include 
those in which the drug identified or designed according to 
the methods described herein are in admixture with a topical 
delivery agent such as lipids, liposomes, fatty acids, fatty 
acid esters, steroids, chelating agents and surfactants. Exem-
plary lipids and liposomes include neutral (e.g. diolcoyl-
phosphatidyl ethanolamine (DOPE), dimyristoylphosphati-
dyl choline (DMPC), distearolyphosphatidyl choline) 
negative (e.g. dimyristoylphosphatidyl glycerol (DMPG)) 
and cationic (e.g. diolcoyltetramethyl-aminopropyl (DO-
TAP), and diolcoyl-phosphatidyl ethanolamine (DOTMA)). 
For topical or other administration, the drug identified or 
designed according to the methods described herein can be 
encapsulated within liposomes or can form complexes 
thereto, in particular to cationic liposomes. Alternatively, the 
drug identified or designed according to the methods 
described herein can be complexed to lipids, in particular to 
cationic lipids. Exemplary fatty acids and esters, pharma-
ceutically acceptable salts thereof, and their uses are further 
described in U.S. Pat. No. 6,287,860, which is hereby 
incorporated by reference in its entirety. 
The formulation of therapeutic compositions and their 
subsequent administration ( dosing) is believed to be within 
25 25 mg/kg body weight, at least about 30 mg/kg body weight, 
at least about 40 mg/kg body weight, at least about 50 mg/kg 
body weight, at least about 75 mg/kg body weight, at least 
about 100 mg/kg body weight, at least about 200 mg/kg 
body weight, at least about 250 mg/kg body weight, at least 
30 about 300 mg/kg body weight, at least about 350 mg/kg 
body weight, at least about 400 mg/kg body weight, at least 
about 450 mg/kg body weight, or at least about 500 mg/kg 
body weight. 
In one embodiment, the drug identified or designed 
35 according to the methods described herein can be adminis-
tered to the subject one time (e.g., as a single injection or 
deposition). Alternatively, administration can be once or 
twice daily to a subject in need thereof for a period of from 
about 2 to about 28 days, or from about 7 to about 10 days, 
40 or from about 7 to about 15 days. It can also be administered 
once or twice daily to a subject for a period of 1, 2, 3, 4, 5, 
6, 7, 8, 9, 10, 11, 12 times per year, or a combination thereof. 
For example, the dosage may be given once or more daily, 
weekly, monthly or yearly, or even once every 2 to 20 years. 
45 In one embodiment, two or more combined the drug iden-
tified or designed according to the methods described herein, 
therapeutics, and the like may be used together in combi-
nation or sequentially. The dosage can vary depending upon 
known factors such as the pharmacodynamic characteristics 
50 of the active ingredient and its mode and route of adminis-
tration; time of administration of active ingredient; age, sex, 
health and weight of the recipient; nature and extent of 
symptoms; kind of concurrent treatment, frequency of treat-
ment and the effect desired; and rate of excretion. Persons of 
55 ordinary skill in the art can easily estimate repetition rates 
for dosing based on measured residence times and concen-
trations of the drug in bodily fluids or tissues. Following 
successful treatment, it may be desirable to have the patient 
undergo maintenance therapy to prevent the recurrence of 
60 the disease state, wherein the drug identified or designed 
according to the methods described herein is administered in 
maintenance doses, ranging from at least about 0.1 mg/kg 
body weight to about 10 mg/kg of body weight, from at least 
about 0.1 mg/kg body weight to about 20 mg/kg of body 
65 weight, from at least about 0.1 mg/kg body weight to about 
30 mg/kg of body weight, from at least about 0.1 mg/kg 
body weight to about 40 mg/kg of body weight, from at least 
US 10,975,412 B2 
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about 0.1 mg/kg body weight to about 50 mg/kg of body 
weight, from at least about 0.1 mg/kg body weight to about 
60 mg/kg of body weight, from at least about 0.1 mg/kg 
body weight to about 70 mg/kg of body weight, from at least 
about 0.1 mg/kg body weight to about 80 mg/kg of body 5 
weight, from at least about 0.1 mg/kg body weight to about 
90 mg/kg of body weight, from at least about 0.1 mg/kg 
body weight to about 100 mg/kg of body weight, once or 
more daily, to once every 2-20 years. 
16 
ments ±0.1 % from the specified amount, as such variations 
are appropriate to perform the disclosed method. 
The terms "animal," "subject," and "patient" as used 
herein includes all members of the animal kingdom includ-
ing, but not limited to, mammals, animals (e.g., cats, dogs, 
horses, swine, etc.) and humans. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
While the terms used herein are believed to be well 10 
understood by those of ordinary skill in the art, certain 
definitions are set forth to facilitate explanation of the 
presently-disclosed subject matter. Unless defined other-
wise, all technical and scientific terms used herein have the 
same meaning as commonly understood by one of ordinary 
skill in the art to which the presently-disclosed subject 
matter belongs. 
two particular units are also disclosed. For example, if 10 
15 and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
Although any methods, devices, and materials similar or 
equivalent to those described herein can be used in the 
practice or testing of the presently-disclosed subject matter, 20 
representative methods, devices, and materials are now 
described. 
In certain instances, nucleotides and polypeptides dis-
closed herein are included in publicly-available databases, 
such as GENBANK® and SWISSPROT. Information 25 
including sequences and other information related to such 
nucleotides and polypeptides included in such publicly-
available databases are expressly incorporated by reference. 
Unless otherwise indicated or apparent the references to 
such publicly-available databases are references to the most 30 
recent version of the database as of the filing date of this 
Application. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as is commonly 
understood by one of skill in the art to which the invention(s) 35 
belong. All patents, patent applications, published applica-
tions and publications, GenBank sequences, databases, web-
sites and other published materials referred to throughout the 
entire disclosure herein, unless noted otherwise, are incor-
porated by reference in their entirety. In the event that there 40 
are a plurality of definitions for terms herein, those in this 
section prevail. Where reference is made to a URL or other 
such identifier or address, it understood that such identifiers 
can change and particular information on the internet can 
come and go, but equivalent information can be found by 45 
searching the internet. Reference thereto evidences the 
availability and public dissemination of such information. 
Following long-standing patent law convention, the terms 
"a", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer- 50 
ence to "a cell" includes a plurality of such cells, and so 
forth. 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 
related to the present invention. 
EXAMPLES 
Materials and Methods 
Preparation of Mutant Genomic dsDNA 
Phi29 genomic DNA-gp3 was purified from B. subtilis 
SpoA12 cells by CsCl gradient ultracentrifugation as 
described previously [63]. Mutant dsDNA was prepared by 
digesting the phi29 genomic dsDNA with EcoRl restriction 
enzyme in fast digest buffer (Fermentas) at 37° C. for 1 hour 
followed by ethanol precipitation. The mutant DNA was 
tested by 1 % agarose gel electrophoresis, stained by 
ethidium bromide (Sigma) and imaged by Typhoon (GE). 
Preparation of Mutant pRNA 
Wild-type phi29 pRNA and inactive mutant as drugged 
pRNA were prepared by in vitro transcription. In the inactive 
mutant pRNA, the first four bases "UUCA" (SEQ ID NO: 1) 
located at the 5' end were mutated to "GGGG" (SEQ ID NO: 
2). Bg!II digested plasmid pRT71 was used as DNA template 
[64] in the PCR reaction for both RNAs. Oligonucleotide 
5'-TAA TAC GAC TCA CTA TAG GGG TGG TAC-3' (SEQ 
ID NO: 3) and 5'-TTA TCAAAG TAG CGT GCA C-3'(SEQ 
ID NO: 4) were used as primers for mutant pRNA. RNAs 
were then transcribed by T7 RNA polymerase using double-
stranded DNA generated from PCR, as described before 
[65]. The RNA from in vitro transcription was further 
purified by 8 M urea 8% polyacrylamide gel electrophoresis 
as described previously [64]. 
Preparation of Mutant ATPase Gp16 
The purification of wild-type gp16 has been described 
previously [63]. The walker B mutant gp16 was constructed 
by introducing mutations in the gp16 gene. The amino acid 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
55 residues D255 and E256 in walker B motif of gp16 were 
mutated to E255 and D256, respectively. The mutation was 
introduced with the Stratagene Quick Change site-directed 
mutagenesis kit using appropriate primers. The expression 
and purification of protein were carried out followed a 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1%, in some embodiments ±0.5%, and in some embodi-
60 published procedure [51]. 
Antisense Oligonucleotides 
Antisense oligonucleotides P3 and P15 were designed to 
be reversely complementary to different regions on the 
pRNA molecule and chemically synthesized by IDT. P3 
65 oligo (5'-TTGCCATGATTGACAAC-3' (SEQ ID NO: 5)) 
targets the region of 83-99 nucleotides at the 3'end of pRNA, 
P15 oligo (5'-AAGTACCGTACCATTGA-3' (SEQ ID NO: 
US 10,975,412 B2 
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6)) targets the region of 1-17 nucleotides at the 5'end of 
pRNA. PS oligo (5'-TAATACGACTCAC-
TATAGGGGTGGTAC-3 (SEQ ID NO: 7)) was designed as 
a non-targeting control in the test. 1 µI of individual oligos 
18 
The Definition of "K Value", and K=l is One Key for 
Ultra-High Inhibition Efficacy 
Suppose a biocomplex drug target contains Z copies of 
subunits, then K is the copy number (KsZ) of drugged 
subunits required to inhibit the function of the complex or 
the nanomachine. As an analogy to the difference between 
the parallel circuit and the serial circuit, when the Christmas 
lights are arranged in a parallel circuit, any light bulbs that 
are burnt out will not affect other bulbs. But in a serial 
at 100 µM were mixed with 1 µI of pRNA at 4 µM and 5 
dialyzed on a 0.025 µm mixed cellulose esters VSWP filter 
membrane (Millipore Corp) against TBE buffer (89 mM 
Tris-HCI, pH 8.3, 89 mM boric acid, 2.5 mM EDTA) at 
room temperature for 15 min. The purified RNA complex 
was used for in vitro phi29 assembly assay. 10 circuit, any one light bulb that is broken will stop the entire 
lighting system, which is K=l. Thus, the K value is the key 
to the probability of inactive nanomachines or biocomplexes 
by combination and permutation of all subunits. K equals 1 
In Vitro Phi29 Assembly Assay 
Purified components were subjected to in vitro viral 
assembly assay as described previously [66]. Briefly, 10 µg 
of purified procapsids were mixed with 100 ng of pRNA in 
is critical for such ultra-high inhibition effect. The founda-
tion of the approach in this report is the difference in 
probability of inhibited biocomplexes in systems of different 
K values with combination and permutation algorithms. 
Biological systems display complicated reactions. Many 
5 µI ofreaction buffer (10 mM ATP, 6 mM 2-mercaptoetha- 15 
no!, and 3 mM spermidine in TMS buffer) at room tempera-
ture for 30 min. Purified DNA-gp3 and gp16 were then 
added and the reaction mixture was incubated at room 
temperature for one hour to initiate DNA packaging. Finally, 
the DNA filled procapsids were incubated with 10 µI of 
gpS.5-9 extract from E. coli containing plasmid pARgpS.5-9 
and 20 µI of gpll-14 extract from E. coli to complete the 
infectious phage assembly. 
20 reactions involve multiple subunits to work cooperatively 
sequentially or processively to accomplish one essential 
biological function [33,68,69, 70, 71, 72, 73, 7 4, 75]. Single 
assembly pathways have been reported in the viral assembly 
system [7 6, 77]. In most cases of the sequential, cooperative, The newly assembled infectious viruses were plated with 
inoculated B. subtilis bacteria su+44 cells onto a half LB 
plate covered with top agar. After 12 hour incubation at 37° 
C., the viral assembly efficiency (plaque-forming unit, PFU) 
was calculated by counting the formed plaque numbers. 
Mixing different ratios of mutant with wild-type compo-
nents, while keeping all other components the same, the 
viral assembly efficiency (PFU) versus ratio of mutant 
components gave an empirical curve for vial assembly 
inhibition assay, and it was compared with theoretical curves 
from the binomial distribution equation. 
In Viva Viral Assembly Assay 
Plasmid pRBwtRNA containing the pRNA coding 
sequence under T7 promoter was constructed by ligating the 
fragment coding pRNA sequence and T7 promoter into 
pRB381-L550 vector (modified and kindly provided by M. 
Wang and H Zalkin) following a previously described 
method [ 67]. Plasmid pRBmutRNA contained mutant 
pRNA under its natural promoter PEI sequence, and the 
mutation was changing sequence 5'UUGA-3' (SEQ ID NO: 
8) at its 3'end to 5'GGGG-3' (SEQ ID NO: 9). The DNA 
fragments coding mutant pRNA sequence and PEI sequence 
were prepared by PCR as described previously[ 67]; and 
digested with HindIII-Bg!II restriction enzyme. The mutant 
pRNA sequence coding fragment was further ligated with a 
6.0 kb fragment from pRB381-L550 that was digested with 
HindIII and partially digested with Bg!II. 
The plasmids pRBmutRNA, pRBwtRNA, and pRB381-
L550 were transformed into B. subtilis cells following 
methods described previously [67]. The B. subtilis cells 
harboring transformed plasmids were incubated in 416 
medium with 10 mg/ml of neomycin for 3 hours at 3 7° C. 
and then plated onto LB-neomycin (10 mg/ml) plates for 
plaque formation analysis. 
Results 
The Definition of "Stoichiometry". 
The definition of the stoichiometry in this report is 
different from conventional definition of stoichiometry used 
to evaluate drug efficiency. Conventionally the concept of 
stoichiometry refers to the number of a drug binding to each 
target molecule, which is also known as Bmax· In this study 
the definition of stoichiometry refers to the copy number of 
subunit within a biocomplex or the nanomachine that serves 
as drug target. 
25 and processive action, inactivation of any one, not necessary 
all, of the subunits will result in inhibition of its function, 
thus K=l. Drug synergism was utilized in multi-target drug 
therapy; in short, a drug combination can simultaneously act 
on multiple targets in disease networks to produce a syner-
30 gistic effect [50,78]. However, our design reported here is 
unique from the conventional synergistic approach. We 
suggest that using multi-subunit biocomplexes as drug target 
could lead to development of ultra-high potent drugs. In a 
35 
conventional six-component system, for example one drug 
is designed to target component #3 to stop the entire system, 
since the drug can only target component #3, the condition 
fits the model of Z=l and K=l. Thus, the inhibition effi-
ciency and substrate targeting efficiency (p) of drug will be 
40 in linear relationship. However, in the system in this report, 
the entire system will be blocked when drug targets any 
subunit of a hexamer, which is Z=6 and K=l. Thus the 
probability of remaining undrugged targets will be q6 , where 
q represents the fraction of untargeted hexamer subunits; in 
45 other words, the drug inhibition efficiency will be l-q6 , 
which increases following a power function compared to the 
linear for conventional mono-subunit approaches. 
Assuming that at least K copies of drugged subunits were 
needed to deactivate the nanomachine or biocomplex, the 
50 probability of functional biocomplexes in the presence of 
various ratios of inhibited and wild-type subunits could be 
predicted from equation 2. When K=l, it implies that drug 
binding to one subunit will inactivate the subunit, and one 
drugged subunit per multi-subunit complex is sufficient to 
55 inhibit the overall function of the complex. The inhibition 
efficiency by drugs targeting multi-subunit biocomplexes 
with stoichiometry of Z will equal l-q2 , as shown in table 
2. An example for such a probability calculation when Z=6 
and K=l is as follows: since it was assumed that 6 (Z=6) 
60 copies of subunits per element were required for function 
and one drugged subunit (K=l) was sufficient to block its 
activity, all elements possessing 1 to 5 copies of drugged 
subunits would be non-functional (FIG. lC). Only those 
complexes possessing 6 copies of normal subunits will be 
65 functional. The chance for a complex containing 6 copies of 
unaffected subunits in a population is q6 and the inhibition 
efficiency will be l-q6 • 
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Rationale Behind Selection of Multi-Subunit Biocom-
plexes as Efficient Drug Targets 
Mechanisms for drug inhibition of organism growth are to 
block or stop an essential biological element from function-
ing. When a drug is designed to target the subunit of a 5 
complex with targeting efficiency p, a fraction of subunits 
will not interact with the drug (a percentile given as g, 
p+q=l) and will remain active and exert their functi_on 
properly. Some biological elements are monomers contam-
ing only one subunit, while other biological elements, such 10 
as the bio-motors of hexameric AAA+ family, consist of 
multiple-subunits [19,34]. Conventional drugs are designed 
to inhibit pathogenesis through targeting of a single subunit 
molecule, such as an enzyme or a structural protein of a 
virus. In this situation, the inhibition efficiency is propor- 15 
tional to the substrate targeting efficiency p and the effect is 
proportional to the first order of p. As described above, in 
most cases of sequential action or cooperatives in multiple 
subunit complexes, inactivation of one, not all, of the 
subunits will result in inhibition of its function. Thus, if 20 
complexes containing Z copies of subunits exercise their 
function in a sequential and cooperative way, then K=l, and 
the fraction of the uninhibited active biocomplex will be q2 , 
20 
Computational results based on the binomial equation are set 
forth herein. The context of the results governs which form 
of the equation is used. 
For example, if Z is 3, the probability of all combinations 
of drugged subunits (M) and undrugged subunits (N; 
M+N=Z) in a given biocomplex entity can be determined by 
. f . 2 (p q)3 3 3 2 3 2 3_1 the expans10n o equat10n : + =p + p q+ pq +q - . 
That is, the probability of a complex element possessing 
three copies of drugged subunits in the population isp3 , two 
copies of drugged and one copy of undrugged or wild-type 
subunit is 3p2q, one copy of drugged and two copies of 
undrugged subunits is 3pq2 , and three copies of undrugged 
subunits is q3 • Assuming there were 70% (p=0.7) of subunits 
inactivated by bound drugs, and 30% (q=0.3) unaffected 
subunits in the population, then the percentage of elements 
possessing at least two copies of normal subunits would be 
the sum of those possessing one copy of drugged and two 
copies of undrugged wild-type subunits, 3pq2 , and those 
a higher order with regards to the stoichiometry. The inhi-
bition proportion will equal l-q2 . 
In this investigation, a well-defined in vitro phi29 viral 
assembly system was used to represent a multi-subunit 
nano-machine target, with the mutant component represent-
ing a target component that have been inactivated by. an 
effective drug. Then, the inhibition efficiencies by targetmg 30 
different elements of the phi29 DNA packaging motor with 
different stoichiometry were compared. The viral assembly 
competition assays combined with binomial distribution 
analysis illustrated the concept that drug targeting functional 
biological complexes of a higher-stoichiometry has a higher 35 
efficiency than drug acting on a single subunit target. 
possessing three copies of native subunits is q3 • That is 
3pq2 +q3=3(0. 7)(0.3 )2 +(0.3 )3=0.216=21.6%. In another 
example, if one complex contains 6 subunits, and 5 out of 
the 6 subunits need to remain uninhibited in order to be 
biologically functional, the active complex ratio in the 
population will be the sum of: 1) the probability of each 
25 element containing 5 undrugged subunits, and 2) the prob-
ability of each element containing 6 undrugged subunits. 
When the target element is a monomer containing only 
one subunit, the inhibition efficiency can be calculated 
through a binomial distribution ( equation 1 ), where p and q 
are the fractions of drugged (substrate targeting efficiency) 
and undrugged (normal active elements) subunits, respec-
tively (p+q=l). 
The probability X in the population displaying a certain 
combination of undrugged versus drugged subunits can be 
predicted by a binomial distribution, as shown in equat~on 2. 
Table 1 shows the probability of a given element with M 
drugged and N undrugged subunits at increasing percentages 
of drugged subunits in the population, considering that the 
total subunits in one element (Z) is 3 or 12. The formula, 
Z! M N 
M!N!p q 
40 (from equation 2) was used to calculate each combination 
probability value, the coefficient 
Z! 
However, when the target element contains multiple sub- 45 
units, a high order binomial distribution (equation 2) is 
applied to calculate the drug inhibition effect by finding the 
ratio of resulted active and inactive complexes, where Z 
represents the total number of subunits (the stoichiometry) 
M!N! 
in this equation can also be calculated using Yang Hui 
Triangle, which is also called Pascal's Triangle, or binomial 
distribution (FIG. 18)[79]. 
In Vitro Virus Assembly System Used for Testing the 
Hypothesis 
in one biocomplex and M represents the number of drugged 50 
subunits in one biocomplex. 
The highly sensitive in vitro phi29 assembly system was 
used to determine the inhibition efficiency of drugs targeting 
, ~ ( Z) Z-M M _ f ( Z! ) Z-M M 
(2) multi-subunit complexes [56,66,76,80]. Bacteriophage 
X = (p+q) = U M p q - ~o M!(Z-M)! p q 
M=O 
Note that the binomial distribution as set forth in equation 
2 may also be expressed as follows: 
Z M Z-M . M -M z z ZI ) 
I (M )p q = I(M!(Z-M)! p q2 
M=O M=O 
55 phi29 DNA packaging motor contains one copy of genomic 
dsDNA, 6 copies of packaging RNA, 6 copies of ATPase 
protein gp16 and more than 10000 copies of ATP. The 
stoichiometry of RNA in phi29 has been proven by exten-
sive studies including single-molecule studies[81] AFM 
60 images (FIG. lD) [82,83], pRNA crystal structure determi-
nation (FIG. lE) [84], and mathematical studies [56]. The 
stoichiometry of gpl 6 in phi29 has been proven by multiple 
approaches including native gel binding, capillary electro-
phoresis assays, Hill constant determination, and by titration 
65 of mutant subunits using binomial distribution [19,33]. 
Many other AAA+ superfamily members have been found to 
be hexamers as well [85,86,87,88,89,90,91], such as a red 
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type rubisco activase AAA+ protein CbbX (FIG. lF) [85], 
MecA-ClpC molecular machine (FIG. 1G)[86]. The copy 
number of ATP molecules was calculated based on the fact 
that 6 ATP molecules are required to package one pitch of 
dsDNA with 10.5 basepairs (bp) [92], thus 1 ATP is used to 5 
package 1.7 bp. The entire phi29 genome is composed of 
19.4 kbp, thus, it is expected that more than 10000 ATP 
molecules are required to package the entire phi29 genome. 
The phi29 DNA nano-motor which packages an entire 
genomic DNA into the procapsid can be treated as a disease 10 
model for drug inhibition efficiency analysis. 
In Vitro Testing of the Hypothesis Using DNA Element 
with Stoichiometry of 1 
The inhibition efficiency of drugs targeting a single sub-
unit substrate was tested by in vitro phi29 assembly inhibi- 15 
tion by mutating the genomic dsDNA (FIG. 2A). Various 
ratios of mutant DNA were mixed with wild-type DNA in in 
vitro viral assembly assays. The empirical curve of viral 
assembly efficiency against drugged mutant DNA ratio fits 
well with the theoretical curve from binomial distribution 20 
for Z=l and K=l (FIG. 2B). This suggests that when 
designing drug targeting the genomic DNA in phi29 nano-
motor, it is expected to be a first order inhibition response. 
Comparing the in vitro phi29 assembly inhibition, by adding 
drugged mutant DNA, with simply diluting wild-type DNA 25 
concentration as a control, revealed that the drugged mutant 
DNA didn't cause much difference (FIG. 2C). The results 
showed that the inhibition effect of drugs targeting the 
substrate with stoichiometry of 1 is minimal. 
In Vitro Testing of the Hypothesis Using RNA Elements 30 
with Stoichiometry of 6 
The pRNA of phi29 contains two domains; a head-loop 
domain essential for procapsid binding and a helix domain 
essential for DNA translocation (FIG. 3A, upper panel) 
[30,93,94]. The right-hand loop and left-hand loop of two 35 
pairing pRNA molecules can interact with each other by 
complementary base pairing. Extensive studies have led to 
the conclusion that 6 copies of pRNA form a hexameric ring 
which binds to the procapsid for virus activity [81,82,83,84]. 
Drugged mutant pRNA was constructed by mutating 4 40 
nucleotide sequences at the 5'end region of pRNA (FIG. 3A, 
lower panel), which has been shown to compete with 
wild-type pRNA for procapsid binding, hut was found to be 
deficient in allowing DNA packaging to occur [ 67]. The 
theoretical curves generated using the expansion of binomial 45 
distribution equation while total subunit number Z is 6 and 
varying K number from 1 to 6 are shown in FIG. 3B. Fitting 
the empirical data from phage assembly efficiency at differ-
ent ratios of drugged mutant pRNAs into the theoretical 
curves, the empirical data fit into the theoretical curve of 50 
Z=6 and K=l. It suggested that the pRNA oligomer ring is 
composed of six copies of pRNA subunits and one subunit 
of the pRNA multimer blockage is sufficient to block the 
phage assembly activity. Comparing the empirical curve for 
viral assembly efficiency against different ratios of drugged 55 
mutant pRNAs with the wild-type pRNA concentration 
dilution control, addition of drugged mutant pRNA showed 
a much stronger inhibition effect (FIG. 3C). 
To further prove the concept that drugs targeting biocom-
plex with high stoichiometry causes stronger inhibition 60 
effect, antisense oligonucleotides which can bind to pRNA 
molecules were designed as mock drugs in the viral assem-
bly assay. The oligonucleotides P15, and P3 were designed 
to target the 5'-end and 3'-end regions on pRNA, respec-
tively. It was confirmed that the antisense oligonucleotides 65 
can be hybridized to pRNA by gel shift assay ( data not 
shown). When mixing the antisense oligonucleotides with 
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wild-type pRNA for in vitro phi29 assembly assay, complete 
inhibition effects were shown by antisense oligonucleotides 
P15, and P3, but not with the non-targeting control oligo-
nucleotide P8[95]. By mixing the non-targeting oligo PS 
with pRNA, it generated plaques with 4.4xl06 PFU on the 
plate. 
In Vivo Testing of the Hypothesis Using RNA Elements 
with Stoichiometry of 6 
Formation of the hexameric ring of pRNA in the phi29 
dsDNA packaging motor has been discovered through bio-
chemical and structural studies [52,81,84,96,97,98,99,100, 
101,102,103] and activity assays [94,104]. The observed 
high inhibition efficiency by drugged mutant pRNA on 
phi29 assembly in vitro was striking [67,105]. To test 
whether such a high level of inhibition was attainable in 
vivo, pRBmutRNA plasmid expressing a pRNA with 4-base 
mutation at the 3' end (FIG. 4A) was transformed into B. 
subtilis DEi cells. Plasmid pRBwtRNA contained the 
pRNA coding sequence but do not express pRNA in B. 
subtilis DEi cells, and vector pRB381-L550 was introduced 
as well as a negative control. The results showed that only 
cells harboring pRBmutRNA plasmid were completely 
resistant to plaque formation by wild-type phi29 virus 
infection. Control cells, includingB. subtilis 12Acells alone, 
B. subtilis DEi cells carrying vector pRB381-L550 alone, 
and cells carrying a wild-type pRNA coding sequence but no 
expression plasmid pRBwtRNA were all positive for plaque 
formation (FIG. 4B). The ability of mutant pRNAs gener-
ated in cells by plasmid pRBmutRNA completely inhibited 
plaque formation indicated that hexameric pRNA in DNA 
packaging nano-motor may be a potential target for devel-
oping potent antiviral agents [67]. 
In Vitro Testing of the Hypothesis Using theATPase with 
Stoichiometry of 6 
Hexameric folding of ATPase gp16 protein in the phi29 
dsDNA packaging motor has been discovered [1,19,33,35]. 
The hexameric gp16 protein complex functions as ATPase 
like many other AAA+ superfamily members. ATP binding 
to one subunit of gp16 stimulates the ATPase to change its 
conformation from having a lower affinity to one having a 
higher affinity for dsDNA. 
Determination of gp 16 stoichiometry was carried out by 
in vitro phage assembly assay and based on the binomial 
distribution of wild-type and Walker B mutant gp16 [51]. 
Different ratios of drugged Walker B mutant gp16 were 
mixed with undrugged gp16 to test the inhibition efficiency 
of gp16 mutation on phi29 DNA packaging motor. Assum-
ing K equals 1 and the total copy number of gp16 (Z) is 
between 1 and 12, twelve theoretical curves for the produc-
tion of phi29 virion against the ratio of the Walker B mutant 
corresponding to the stoichiometry (Z) of 1 to 12 were 
generated according to equation 2. The empirical data nearly 
perfectly overlapped the theoretical curve of Z=6, K=1[51]. 
This data suggested that the ATPase gp16 components of 
phi29 DNA packaging motor have a stoichiometry of six, 
and only one copy of the drugged gp16 can block the phi29 
motor function. Comparing the inhibition effect of adding 
mutant gp16 with wild-type gp16 at different concentrations, 
it showed that adding mutant gp16 had a much stronger 
inhibition effect than the wild-type gp16 concentration dilu-
tion control (FIG. SA). Comparing the inhibition effect of 
mutation on hexameric gp16 to the effect of mutation on 
single subunit target DNA, the gp16 mutation displayed a 
much stronger inhibition effect on virus assembly than the 
same ratio of DNA mutation, indicating the hexameric 
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ATPase protein complex of virus assembly system should 
also be an efficient target for generating new anti-virus drugs 
with high potency. 
In Vitro Testing of the Hypothesis Using ATP with Stoi-
chiometry of More than 10000 
It has been reported that 6 ATP molecules are required to 
package one pitch of dsDNA with 10.5 bp [90], thus 1 ATP 
is used to package 1.7 bp. As the entire phi29 genomic DNA 
has 19,000 base pairs, it is expected that more than 10000 
ATP molecules are required to package the entire phi29 
genome. Since concerning ATP, the functional unit displayed 
in FIG.Sis the viral production expressed as plaque-forming 
unit (PFU), so the production of one functional unit of PFU 
require 10000 ATP subunits to package one genomic DNA. 
Thus, the ATP in one phi29 nanomotor can be regarded as a 
stoichiometry of 10000. One non-hydrolysable ATP ana-
logue y-S-ATP was treated as the drugged subunit that mixed 
with ATP at different ratios to test the inhibition effect of 
y-S-ATP on phi29 assembly efficiency. It was found that the 
inhibition curve of mutant ATP fits into the theoretical curve 
between Z=l00. K=l and Z=60. K=l (FIG. SB). The empiri-
cal ATP value derived from binomial distribution assay was 
different from real condition, since the binomial distribution 
equation was based on a condition that each subunits has the 
same binding affinity to the biocomplex in the targeted 
nanomotor, but due to the change of the y-S-ATP structure, 
it has a ATPase gp 16 binding affinity lower than the normal 
ATP. Furthermore, the affinity difference in each subunit has 
a multiplicative effect in the nanomotor's activity. Thus, 
there is a big discrepancy between the curves with predicted 
Z value and the empirical Z value. 
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For Z=l, K=l, the proportion of inhibited complex is 
l-q2 =1-0.1=0.9. The proportion of non-inhibited complex 
is q2 =0.1. The ratio of inhibition efficiency equals to lE-6/ 
0.l=lE-5, indicating a 10000-fold increase in inhibition 
5 efficiency (Table 3 ). 
The equation displays inhibitory effect with a power 
function of stoichiometry since when K = 1, the percentage of 
uninhibited biocomplexes in the population equal to q2 • 
Since (P+q)=l, thus qsl, thus the larger the Z, the smaller 
10 the value of q2 That is to say, the higher the stoichiometry, 
the smaller number of the uninhibited background will 
display. With the same substrate targeting efficacy, p, the 
inhibition efficiency is determined by z, the power of the 
equation component. The inhibitory effect is a power func-
15 tion concerning the stoichiometry. Thus, the higher the 
stoichiometry, the more efficient the inhibition comparing 
the drugs with same binding affinity. 
The half maximal inhibitory concentration (IC50) is com-
monly used to evaluate drug effect, which quantitatively 
20 indicates how much of a particular drug is needed to inhibit 
a given biological process by half. Ifwe denote Picso as the 
percentage of drugged subunit needed to reach to 50% 
inhibition in the in vitro assay in the defined system, thus 
l-(1-Picsof=50%. Solving this equation, Picso=l-0.5 112. 
25 FIG. 6 shows the relationship between stoichiometry (Z) and 
drug targeting level p to reach the inhibition effect (IC), 
where p is the combined result of drug binding efficacy and 
drug concentration (dosage). When biocomplexes with stoi-
chiometry of Z are used as drug targets, the dosage of drug 
30 or the drug binding affinity presented by percentage of 
drugged subunits to reach IC50, IC25 , or IC75 decreases. This 
clearly shows that as Z increases, decreases (FIG. 6), and 
hence the drug is more potent. 
Comparing virus assembly inhibition effect using differ-
ent components, the y-S-ATP showed a severe inhibition 
effect (FIG. SC). Adding 20% of gamma-s-ATP nearly 
completely inhibited the viral assembly. Comparing the 35 
inhibition effect targeting to ATP, pRNA, ATPase gpl 6, and 
DNA with stoichiometry of 10000, 6, 6, and 1, respectively, 
y-S-ATP showed the strongest inhibition effect, while 
drugged mutant pRNA and mutant gp16 showed stronger 
inhibitory effect than mutant DNA (FIG. SC). For example, 
adding 20% mutant DNA caused 20% inhibition effect in 
viral assembly, while 20% of drugged mutant pRNA exerted 
74% of inhibition effect on viral assembly and 20% of 
y-S-ATP almost completely inhibited the viral assembly, 
indicating the higher the stoichiometry, the stronger the 
inhibition efficacy. 
Discussion 
Aiming to find a method for developing drugs with 
ultra-high potency, we proposed that the inhibition effi-
ciency of a given drug depends on stoichiometry of the 
biocomplex or bio-machine that was used as drug target. 
Here the definition of the stoichiometry is different from 
40 conventional definition of stoichiometry used to evaluate 
drug efficiency. Conventional thinking in drug development 
emphasizes stoichiometry which refers to the number of 
drug binding per target molecule, which is also known as 
Bmax· In this study the definition of stoichiometry refers to 
45 the copy number of subunit within a biocomplex that serves 
as drug target. We used phi29 viral components with a series 
of variable but known stoichiometry as mock drug targets to 
test the hypothesis. Both in vitro and in vivo virion assembly 
assays were employed to compare the inhibition efficiency 
Mathematical Reasoning for the Increase of Inhibition 
Efficacy 
Using a biological complex with higher stoichiometry as 
drug target will substantially reduce the proportion of non-
inhibited complex. For K=l, the proportion of non-inhibited 
complex is q2 . Table 3 compares the proportion of non-
inhibited complex from two populations with Z=6 and Z=l, 
respectively, with varied substrate targeting efficiency (p) 
when K=l. For example, when q=0.4, the proportion of 
non-inhibited complex is q2 =0.4 1=0.4 for Z=l. K=l. There-
fore, only 1-0.4=60% of complex is inhibited. In contrast, 
for Z=6, K=l, the proportion of non-inhibited complex is 
q2 =0.46=0.0041. Therefore, 1-0.0041=99.59% of complex 
is inhibited. The ratio of the proportions of non-inhibited 
complex equals 0.0041/0.4=0.0102, indicating a 
1/0.0102=98-fold decrease in the proportion of non-inhib-
ited complex. One more example is to use the drug targeting 
efficiency p=0.9 to compare the inhibition efficiency 
between two groups with Z=6 and Z=l. For Z=6, K=l, the 
proportion of inhibited complex is l-q2 =1-0.l 6=0.999999. 
The proportion of non-inhibited complex is q2 =0.l 6=1E-6. 
50 targeting to components with different numbers of subunit 
stoichiometry. Viral inhibition efficiency was analyzed with 
Yang Hui's (Pascal's) Triangle (or knowns as binomial 
distribution). It was found that inhibition efficiency on virus 
replication correlates to the component stoichiometry of 
55 nano-machine as drug target. It displayed power law inhibi-
tory effect since when K=l, the percentage of uninhibited 
biocomplexes in the population equal to q2 • With the same 
q and same K value, the inhibition efficiency is determined 
by z, the number of subunits within the biocomplex or the 
60 bio-machine as drug target. Here z serves as the power in the 
equation, thus, the inhibitory effect is the power of the 
stoichiometry. Empirical data demonstrated that the target 
with thousand-subunits shows higher inhibition effect than 
the targets with six subunits, and in turn higher than the 
65 target with single subunit. 
In evaluation of drug effect, two parameters were com-
monly used. One is the half maximal inhibitory concentra-
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tion (IC50), which quantitatively indicates how much of a 
particular drug is needed to inhibit a given biological 
process by half. It is universally used as a measure of drug 
potency in pharmacological research. Another important 
parameter is the median lethal dose (LD50), which is also 5 
known as 50% of lethal concentration (LC50). LD50 is 
frequently used to indicate a substance's acute toxicity. 
Obviously, the usefulness of a drug will dependent on the 
ratio of LD50 to IC50 . The larger this ratio, the safer the drug. 
By ways of increasing the inhibition efficiency through 10 
targeting to the components with high stoichiometry, the 
IC50 of a drug will decrease. As a result, lower concentration 
of drug will be required for reaching a desired effect, 
resulting in a reduced toxicity of the drug. 
Most of current anti-cancer, anti-virus or anti-bacteria 15 
drugs target single enzymes or single proteins. Our data 
showed that drugs selected to target components, biocom-
plexes, or nano-machines with high copy numbers could 
lead to a much higher efficacy, and it could potentially solve 
the problem of low drug effect and multi-drug resistance. 20 
Conclusions 
Targeting the functional biological units with higher stoi-
chiometries will have a higher efficiency of inhibition. The 
inhibition effect is power, other than proportional, and the 
power, is the copy number of the drug-targeted element of 25 
the machine. The new theory developed herein suggests that 
potent drugs can be developed by targeting biocomplex with 
high stoichiometry, and a complete inhibition of virus, 
bacterium, or cancer is possible if a bio-machine with high 
stoichiometry is identified. Since bio-motors share certain 30 
common structure and operation mechanism in viruses, 
bacteria, and cells, this approach should have general appli-
cation in drug development. 
Living systems contain many elegant arrays, motors and 
nanomachines that are multi-subunit complex. As reported 35 
here, these biocomplex with high copy number of compo-
nents can serve as potent drug targets. For example, most 
members of the AAA+ family are hexamer [19,87,88,106, 
107,108]. However, these machines are common in living 
systems therefore the specificity and toxicity is an issue. For 40 
bacteria and virus, since our goal is to kill them nonexclu-
sively, the specificity and toxicity is not an issue as long as 
the target biocomplex is not identical to that in human body. 
For cancers drugs, as long as a mutation is found in the 
multiple-subunit biocomplex, it will be an ideal target for 45 
potent drug. 
Disclosed Method(s) 
A method is disclosed herein for developing potent drugs. 
Drug inhibition potency depends on the stoichiometry of the 
targeted biocomplex. 50 
Approach: 
Phi29 viral components with variable stoichiometry were 
used as model to prove the hypothesis. Virion assembly 
efficiency was assayed and analyzed with Yang Hui's Tri-
angle: 55 
26 
thousand-subunit showed higher inhibition effect than with 
six subunits, and in turn higher than target with single 
subunit. A complete inhibition of virus, bacterium, or cancer 
was demonstrated when targets with high stoichiometry was 
used as target. 
Conclusions 
Drug inhibition potency depends on the stoichiometry of 
the targeted components of the biocomplex or nano-ma-
chine. The inhibition effect displayed a power function of 
the stoichiometry of the target biocomplex. Since bin-
motors share certain common structure and operation 
mechanism in viruses, bacteria, and cells, this approach 
should have general application in drug development. 
Section 2 
Multidrug resistance and the appearance of incurable 
diseases inspire the quest for potent therapeutics. 
A new methodology in designing potent drugs is devel-
oped by targeting multi-subunit homomeric biological 
motors, machines, or complexes with Z>l and K=l, where 
Z is the stoichiometry of the target, and K is the number of 
drugged subunits required to block the function of the 
complex. The condition is similar to the series electrical 
circuit of Christmas decorations; failure of one light bulb 
results in power-off of the entire lighting system. In most 
multisubunit homomeric biological systems, a sequential 
coordination or cooperative action mechanism is utilized, 
thus K equals 1. Drug inhibition depends on the ratio of 
drugged to non-drugged complexes. When K=l, and Z>l, 
the i_nhibition effect follows a power law with respect to z, 
leadmg to enhanced drug potency. The hypothesis that the 
potency of drug inhibition depends on the stoichiometry of 
the targeted biological complexes was recently quantified by 
Yang-Hui's Triangle (or binomial distribution), and proved 
using a highly sensitive in vitro phi29 viral DNA packaging 
system. Examples of targeting homomeric bio-complexes 
with high stoichiometry for potent drug discovery are dis-
cussed. 
Biomotors with multiple subunits are widespread in 
viruses, bacteria, and cells, making this approach generally 
applicable in the development of inhibition drugs with high 
efficiency. 
The continuous escalation of drug resistance has been 
threatening human health and life, i.e., many microorgan-
isms including bacteria, viruses, and even cancer cells are 
developing resistance to current chemotherapies. Drug resis-
tance in cancer has partially contributed to -600,000 deaths 
in the USA in 2012[1]. To combat the on-rising drug 
resistance, different approaches for developing new drugs 
have been explored. One method is to develop drugs that 
target new mechanisms. Components highly important for 
cancer cell growth have been explored as drug targets for the 
treatment of multi drug resistant cancer[2, 3]. The first 1-DA-
approved drug to treat multidrug-resistant tuberculosis, 
bedaquiline, follows a new mechanism of inhibiting the 
bacterial ATP synthase of M. tuberculosis and other myco-
bacterial species[ 4]. Another approach is to use nano-drug 
carriers to enhance the binding efficiency of drugs to cancer 
cells[5-8]. A third approach is to develop new combinational 
drugs acting on multiple targets to enhance its efficacy [9, 
Results: 
Inhibition efficiency displayed a power function of the 
stoichiometry of the target biocomplexes. The uninhibited 
biocomplex in population can equals to q2 • Thus, the inhibi-
tory effect is a power of the stoichiometry. Targets with 
60 ~OJ, incl~ding cocktail therapy[ll]. This involves identify-
mg multiple targets that when treated simultaneously lead to 
a synergetic therapeutic effect and optimizing the design of 
multi-target ligands[12]. Still, there is unmet need for treat-
ing multi-drug resistant disease. Thus, new approaches for 
65 drug development are needed to combat drug resistance. 
A new hypothesis that potent drugs can be developed by 
targeting proteins or RNA complexes with high subunit 
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stoichiometry was reported recently[13]. The major chal-
lenge for testing this hypothesis is to evaluate the signifi-
cance of the target stoichiometry and the binding affinity of 
the drug molecule with respect to its efficacy. In order to 
quantitatively correlate the drug inhibitory efficacy to the 5 
stoichiometry of the target biocomplexes, a well-studied 
multicomponent system is required, which allows an empiri-
cal comparison of functional inhibition efficiency of indi-
vidual components with different numbers of subunits. 
The DNA packaging motor of bacteriophage phi29 was an 10 
ideal model for testing this theory. The morphology and 
stoichiometry of the individual components in the phi29 
DNA packaging motor have been well studied. The Phi29 
biomotor (FIG. lA) is composed of three essential, co-
15 
axially stacked rings[14-17]: a dodecameric connector ring 
located at the vertex of the viral procapsid; a hexameric 
packaging RN A (pRNA) ring bound to the N-terminus of the 
connector[16, 18], and a hexameric ring of ATPase gp16 
attached to the helical region ofpRNA[19-21]. The stoichi- 20 
ometry of pRNA was first determined using Yang Hui's 
Triangle (or binomial distribution) in 1997[22], and similar 
mathematical methods were applied to determine the stoi-
chiometries of the protein subunits [14]. Furthermore, 
dsDNA packaging utilizes a revolution mechanism without 25 
rotation to translocate its genomic DNA powered through 
the hydrolysis of ATP[20, 21, 23-28]. The copy number of 
ATP molecules required to package one full Phi29 genomic 
dsDNA has been predicted to be 10,000[20, 21, 23-27, 29]. 
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43]; inhibiting any subunit leads to inhibition of the entire 
complex, or in other words K equals 1. 
For a conventional drug that inhibits its single subunit 
target (Z=l) with efficiency p, the fraction of undrugged 
target molecules q will be 1-p; and those undrugged target 
molecules will remain active to maintain their biological 
function. In this situation, the inhibition efficiency is pro-
portional to the substrate targeting efficiency p[39-41]. 
When targeting a dimeric complex (Z=2), for example, 
inactivating any subunit results in inhibition of the whole 
complex. For a drug targeting a dimeric complex with 
substrate targeting efficiency p=0.9 (90%), only 10% of the 
first subunit and 10% of the second subunit remain active 
after drug targeting. Thus, the fraction of undrugged com-
plexes will be effectively reduced to 0.01, leaving 1 % of 
complexes active. Since drug inhibition depends on the ratio 
of drugged to undrugged complexes, the efficiency of the 
inhibition is proportional to the product of the inhibition of 
the individual subunits, in other words, it follows a power 
law with respect to Z. 
Consequently, a complex composed of Z subunits with the 
smallest number of blocked subunits (K) to inhibit activity 
of the complex is 1, when p percent of subunits are inter-
acting with the drugs, the fraction of uninhibited biocom-
plexes will be q2 and the proportion of inhibition equals 
1-qz. 
2.1 Drug Inhibition Efficiency Predicted by Binomial 
Distribution Model 
The scenario outlined above follows a binomial distribu-
Phi29 DNA packaging, thus, offers an ideal platform to test 30 tion which can hence be used to outline the relation between 
the concept described above: the dependence of the inhibi-
tory drug efficiency on the stoichiometry of its targeted 
biocomplex. 
Although the theory of targeting multisubunit complexes 
for developing potent drugs was reported and validated 35 
recently[13], real cases of targeting multisubunit complex 
for new drug development have been practiced[30-32]. 
Since multicomponent biomotors are widely spread in 
nature[26, 27, 33, 34], the approach of targeting multisub-
unit complexes for potent drug development discussed here 40 
is generally applicable, especially in developing new gen-
erations of drugs for combating the rising acquired drug 
resistance in viruses, bacteria, and cancers [35-37]. 
Rationale for Selection of Multi-Subunit Biocomplexes as 
Efficient Drug Targets 
Inhibitory drugs are typically designed to bind selectively 
to a target site, thereby blocking the site from interaction 
with other biomolecules leads to the loss of essential activity 
of the biological target. This target can be a single element, 
45 
composed of only one subunit, or a complex consisted of 50 
multiple subunits, such as the biomotors of the hexameric 
ASCE (Additional Strand Catalytic E) superfamily[20, 38]. 
Conventional drugs are designed to inhibit pathogenesis 
through targeting of a single subunit molecule, such as an 
enzyme or a structural protein of a virus. As discussed 55 
below, the key in designing potent drugs lies in targeting 
multisubunit biological motors, machines, or complexes as 
drug targets that follow a sequential coordination or coop-
erative mechanism. The stoichiometry of the complex, Z, is 
larger than 1 and the number of drugged subunits that are 60 
required to block the activity of the target complex, K, 
equals 1 (Z> 1 and K = 1 ). Similar to in-series connected 
decorative Christmas lights, where one broken light bulb 
will tum off the entire chain, one drugged subunit will 
inhibit the entire complex and therefore biological activity. 65 
Sequential action or cooperativity in multisubunit com-
plexes has been widely reported in biological systems[39-
drug inhibition efficiency and target stoichiometry in gen-
eral. When the target element is a monomer, the inhibition 
efficiency can be calculated using Equation 1, where p and 
q are the fractions of drugged (substrate targeting efficiency) 
and undrugged (normal active elements) subunits, respec-
tively (p+q=l). 
However, when the target element contains multiple sub-
units, a higher order binomial distribution (Equation 2) is 
required to calculate the ratio of active complexes, where Z 
represents the total number of subunits (the stoichiometry) 
and M the number of drugged subunits in one biocomplex. 
z z z Z! 
X = (p + qj2 = ~ ( )pz-M qM = '\' (----)pZ-M qM U M L, M!(Z-M)! 
M=O M=O 
(2) 
Note that the binomial distribution as set forth in equation 
2 may also be expressed as follows: 
~ ( z) M ,Z-M ~( Z! ) M ,Z-M U M p ~ = U M!(Z-M)! p ~ 
M=O M=O 
Computational results based on the binomial equation are set 
forth herein. The context of the results governs which form 
of the equation is used. 
The probability of drugged subunits (M) and undrugged 
subunits (N; M+N=Z) in any given biocomplex can be 
determined by the expansion of Equation 2. When Z=3, The 
expanded form of Equation 2, (p+q)3=p3 +3p2q+2pq2 +q3 =1, 
displays the probabilities of all possible combinations of 
drugged and undrugged subunits of a homotemary complex 
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composed of three (p3 ), two (p2 q), one (pq2 ), or no (q3 ) 
drugged subunits; the sum equals 1. Assuming that 70% 
(p=0.7) of subunits are inactivated by bound drugs leaving 
30% (q=0.3) unaffected, then the percentage of complexes 
possessing at least two copies of normal subunits would be 5 
the sum of those possessing one copy of drugged and two 
copies of undrugged wild-type subunits, 3pq2 , and those 
possessing three copies of native subunits is q3 , i.e., 3pq2+ 
q3=3(0.7)(0.3)2+(0.3)3=0.216. In another example, if a 
complex contains 6 subunits, and biological activity requires 10 
5 out of the 6 subunits to remain uninhibited, the fraction of 
active complexes in the total population equals the sum of 
probabilities of obtaining: 1) 5 and 2) 6 undrugged subunits. 
nature of biological reactions, we suggest that targeting of 
multi-subunit biocomplexes can serve as a tool to develop 
highly potent drugs. In a conventional six-component sys-
tem, when one drug is designed to target only the component 
#3 to stop the entire system, such a condition resembles the 
model in equation 2 with Z= 1 and K = 1. Thus, the inhibition 
efficiency is linear to the substrate targeting efficiency (p) of 
the drug. However, in a homohexameric component system, 
the entire complex is blocked when a drug targets any 
subunit of the hexamer, which resembles Z=6 and K=l. 
Thus, the probability of active target complexes equals q6 
(q=l-p). In other words, the drug inhibition efficiency is 
equal to l-q6, which scales with the 6th power of q compared 
to linearly with q as for conventional mono-subunit 
approaches (see Table 1). 
Using the binomial distribution, the probabilities that a 
population contains any combination of undrugged versus 15 
drugged subunits can be predicted. The effect of the target-
ing efficiency p on the probability of obtaining a given 
complex with M drugged and N undrugged subunits is 
displayed in Table 1. The probabilities are calculated using 
equation 2, 20 
Targeting a biological complex that exhibits a higher 
stoichiometry substantially reduces the fraction of non-
inhibited complexes. K=l implies that drug binding to one 
subunit inactivates the subunit, in which one drugged sub-
unit is sufficient to inhibit the function of the entire complex. 
As an example, a probability calculation for Z=6 and K=l is 
Z! MN 
M!N!p q' 
with the coefficients 
Z! 
M!N! 
obtained from Yang Hui's Triangle, which is also called 
Pascal's Triangle, or binomial distribution (FIG. 18)[44]. 
The use of Yang Hui's Triangle and binomial distribution to 
determine the stoichiometry of biological motor was pub-
lished in Guo Lab in 1997[22, 45] for RNA component and 
restated in 2014 for protein component[14] in phi29 DNA 
packaging motor. 
2.2 Cooperativity in Multisubunit Biocomplexes Leads to 
High Inhibition Efficiency 
The cooperativity of multisubunit biocomplexes is the 
key to high drug inhibition efficiency. Cooperativity means 
that multiple subunits work sequentially or processively to 
accomplish one essential biological reaction [23, 40-42, 
46-50]. Blocking any subunit of the complex inhibits the 
activity of the whole complex. Many reactions involving 
multiple subunits work cooperatively, e.g. assembly path-
ways in viral assembly systems [39, 51]. An analogy to such 
a biological reaction mechanism is given by the difference 
between parallel and series circuits. When a chain of light 
bulbs is arranged in a parallel circuit, burning out one light 
bulb will not affect others, while in a series circuit, breaking 
any one light bulb turns off the entire lighting system. The 
given below. As all 6 (Z=6) copies of the subunits are 
required for function, while one drugged subunit (K=l) is 
sufficient to block the activity, all elements possessing 1 
25 through 5 copies of drugged subunits are non-functional 
(FIG. lC). Only those complexes possessing 6 copies of 
undrugged subunits are functional. The probability that a 
complex contains 6 copies of unaffected subunits is q6 and 
therefore the inhibition efficiency is l-q6 [12, 23, 39, 46, 51, 
30 52]. 
Consequently, for a drug with binding efficiency p, a 
larger stoichiometry of the target complex substantially 
increases the inhibition efficiency. To illustrate, we compare 
the fraction of non-inhibited complexes for Z=6 and Z=l, 
35 while keeping q=0.4 and K=l fixed for both target systems. 
The fraction of non-inhibited complexes for Z=l amounts to 
q2 =0.4 1=0.4, resulting in 1-0.4=60% of inhibited com-
plexes. In contrast, for Z=6, the fraction of non-inhibited 
complexes is q2 =0.46=0.0041 and therefore 
40 1-0.0041=99.59% of complexes are inhibited. The ratio of 
the remaining non-inhibited complexes (0.4/0.0041 =98) 
shows a 98-fold decrease in non-inhibited complexes for 
Z=6 compared to Z=l. At a targeting efficiency ofp=0.9, the 
inhibition efficiency for Z=6 is l-q2 =1-0.l 6=0.999999 
45 resulting in a 10,000-fold increased inhibition efficiency 
compared to Z=l (0.1/0.1 6=105 , see Table 1). The binomial 
distribution indicates that the inhibitory effect follows a 
power law with respect to the stoichiometry of the target. 
Thus, for K=l, the fraction of uninhibited biocomplexes 
50 equals q2 ; the larger Z, the smaller q2 , (as 0<q<l). That is to 
say when developing drugs with the same binding affinity to 
their targets, the higher the stoichiometry of its multimeric 
target, the fewer uninhibited targets will remain and the 
more efficient the drug will be. 
K value, the smallest number of subunits that needs to be 55 
inhibited in order to inhibit function of the light chain is 
therefore, K=l. Thus, the K value is a key factor in esti-
mating the probability of obtaining inactive nanomachines 
2.3 IC50 Decreases as the Stoichiometry of Target Com-
plexes Increases 
The half maximal inhibitory concentration (IC50) is one 
parameter used to evaluate drug efficacy. It quantitatively 
indicates how much of a particular drug is required to reduce or biocomplexes by combination and permutation of all 
subunits. 
K=l is critical for obtaining ultrahigh inhibition. The 
foundation of the approach in this report is the difference in 
inhibition probability for biocomplexes with the same ratio 
of drugged target subunits but different K values. Biological 
systems display complicated reactions that involve several 
steps and multiple components interacting in series or par-
allel Based on the binomial math model and cooperative 
60 the activity of a given biological process by half. It is 
universally used as a measurement of drug potency in 
pharmacological research. The median lethal dose LD50 , 
also known as 50% of lethal concentration, is an important 
parameter to evaluate the safety profile, i.e., acute toxicity of 
65 a drug. Most importantly, a larger ratio of LD50 to IC50 , 
results in a safer drug. By increasing the inhibition efficiency 
through targeting components with high stoichiometry, the 
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effective drug dosage is greatly decreased, thus decreasing 
the IC50 . As a result, the ratio of LD50 to IC50 increases, 
resulting in an enlarged therapeutic window of the drug. 
32 
drug inhibition efficiency versus the subunit stoichiometry 
of individual subcomponents within the same assay. 
Inhibition efficiencies were determined for ATP, pRNA, 
ATPase gp 16, and DNA as drug targets with stoichiometries Ifwe denote Picso as the percentage of drugged subunits 
needed to reach 50% inhibition, then l-(1-Picso)2=50% 
Solving this equation Picso=l-0.5 112. FIG. 8, shows the 
relationship between stoichiometry (Z) and drug targeting 
level p to reach the inhibition effect (IC), where p is a 
combined result of drug binding efficacy and drug concen-
tration (dosage). When the stoichiometry Z of the multim-
eric drug target increases, the dosage of drug to reach IC50 , 
IC20 , or IC80 decreases, presented by the percentage of 
drugged subunits. This clearly shows that as Z increases, 
Picso decreases, and hence the drug is more potent. 
5 of 10,000, 6, 6, and 1, respectively. Among these compo-
nents, targeting of ATP showed the strongest inhibition, 
while drugged mutant pRNA and mutant gp16 still showed 
stronger inhibitory effects than mutant DNA (FIG. 3). For 
example, adding 20% mutant DNA caused 20% inhibition of 
10 viral assembly, while 20% of drugged mutant pRNA exerted 
74% of inhibition on viral assembly and 20% of y-S-ATP 
almost completely inhibited the viral assembly, indicating 
that higher stoichiometry results in stronger inhibition effi-
Focusing on the stoichiometry of the target complex for 15 
drug development differs from conventional approaches. 
Conventional drug molecules are sought to have a high 
binding affinity to the target, which means we expect more 
drug molecules to bind to one target molecule. Here stoi-
chiometry refers to the copy number of subunits within a 20 
biocomplex or nanomachine that serves as the drug target. 
This idea agrees with a newer model for predicting clinical 
drug efficacy, the receptor occupancy. Receptor occupancy 
acts as a predictor for human pharmacodynamics and anti-
histamine potency and takes into account both the affinity of 25 
the drug for its receptor and its free plasma concentration 
[53]. 
Inhibition Efficiency as a Power Function of Target Stoi-
chiometry Proved by Phi29 Viral Assembly System 
The hypothesis that drug inhibition efficiency follows a 30 
power function with respect to the target stoichiometry has 
been proved using the Phi29 viral assembly system [54]. 
This well-defined in vitro assembly system is composed of 
four components, each of which is comprised of different 
subunits that can act as the nano-machine target. Inhibition 35 
of viral assembly is achieved using mutant components that 
represent drugged target components. The inhibition effi-
ciencies were analyzed with Yang Hui's triangle for target-
ing each of the Phi29 DNA packaging motor components. 
Binomial distribution analysis of these viral assembly com- 40 
petition assays confirmed the concept that drug targeting 
biological complexes with higher stoichiometry results in a 
higher efficiency than drugs acting on a single subunit target. 
The highly sensitive in vitro Phi29 assembly system was 
used to determine the inhibition efficiency of drugs targeting 45 
multi-subunit complexes [22, 39, 45, 55], thus validating a 
new method for developing potent drugs. The bacteriophage 
Phi29 DNA packaging motor contains one copy of genomic 
dsDNA, 6 copies of packaging RNA, 6 copies of ATPase 
protein gpl 6, and consumes more than 10,000 copies of ATP 50 
during genome packaging. The hexameric stoichiometry of 
Phi29 pRNA has been extensively shown using single-
molecule techniques[54], AFM imaging[56, 57], pRNA 
crystal structure determination[58], and statistical evalua-
tions[22]. The hexameric stoichiometry of Phi29 gp16 has 55 
been proved by native gel binding, capillary electrophoresis 
assays, Hill constant determination, and by titration of 
mutant subunits using binomial distribution[20, 23]. The 
copy number of ATP molecules was calculated based on the 
fact that 6 ATP molecules are required to package one pitch 60 
of dsDNA containing 10.5 base pairs [59], thus one ATP is 
used to package 1. 7 base pairs of dsDNA. The entire Phi29 
genome is composed of 19,400 base pairs, thus, it is 
expected that more than 10,000 ATP molecules are required 
to package an entire Phi29 genome. The availability of a 65 
motor system with multiple well-defined and characterized 
components makes an ideal disease model for the analysis of 
cacy. 
The target with ten-thousand-subunits showed higher 
inhibition than those with six subunits, which in tum showed 
higher inhibition than the single subunit target. In conclu-
sion, these results show that inhibition efficiency displays a 
power function with respect to the stoichiometry of the 
target biocomplexes. Drug inhibition potency depends on 
the stoichiometry of the targeted components of the bio-
complex or nano-machine. Since bio-motors share certain 
common structural and operational mechanisms across 
viruses, bacteria, and other cells, this approach has general 
application in drug development. 
Wide-Spread Distribution of Biomotors with Multiple 
Subunits or High Order Stoichiometry 
Biological systems contain a wide variety of nanoma-
chines with highly ordered stoichiometry that are essential 
for DNA replication, DNA repair[60], homologous recom-
bination, cell mitosis, bacterial binary fission, Holliday 
junction resolution[61], viral genome packaging[62], RNA 
transcription, nuclear pore transport, as well as motion, 
trafficking, and exportation of cellular components. Here we 
use biological motors as an example to elucidate the ratio-
nale of Z> 1 and K = 1. These biological motors can generally 
be classified into three categories according to their DNA 
transportation mechanism: linear motors, rotation motors 
and the newly discovered revolution motors[23, 27, 34]. 
High order stoichiometries are wildly observed among bio-
motors, especially in rotation and revolution motors. Thus, 
biomotors are feasible targets for the development of potent 
inhibitory drugs that exploit the power law behavior of the 
subunit stoichiometry. 
4.1 Rotation Nanomachines 
FoFl ATP synthase and helicases are representatives of 
rotary motors [63, 64]. FoFl ATP synthase is a ubiquitous 
membrane enzyme that plays a key role in biological energy 
metabolism [ 65, 66]. It consists of two linked rotary motors, 
Fl and Fe, which are distinct in structure and function. Fl 
ATPase, forming the catalytic core, shows strong ATP 
hydrolysis activity. It is composed of 5 subunits 
(a3 ~ 3 y1 01 E 1), with three a and three~ subunits forming a 
hexameric ring with part of a long coiled coil y subunit. Fo 
is the proton pore that is embedded in the membrane, it 
consists of at least 3 subunits (a1b1 c8 _15 ) whereby subunit c 
differs among species. 
Helicase DnaB is a hexameric nanomachine (FIG. 4A) 
that unwinds dsDNA in front of the replication fork during 
DNAreplication[67, 68]. Recently, a hand-over-hand trans-
location mechanism was proposed for DnaB based on the 
crystal structure of the DnaB hexamer complexed with 
ssDNA and GDP-AIF4 [69]. In this mechanism, the 5'-3' 
translocation of the subunits at a stepsize of two nucleotides 
is coupled with the sequential hydrolysis of NTP [70]. The 
sequential hand-by-hand migration of the individual sub-
units results in DNA translocation. 
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RecA, a family of ATP-dependent recombinases, plays an 
important role in dsDNA repair and genetic recombination 
34 
The ATP-sensitive homotrimeric P2X7 receptor (P2X7R) 
acts as a ligand-gated ion channel. It forms a chalice-like 
channel with three ATP binding sites localized at the inter-
face of the three subunits. Occupancy of at least two of the 
in Archaea, Bacteria, and Eukaryota. It can interact with 
ssDNA forming right-handed helical filaments as a complex 
with approximately six monomers of RecA per turn (FIG. 
48)[71, 72]. Electron microscopy studies have demonstrated 
that ATP binding induces a re-orientation between the RecA 
ATPase domains, resulting in the relative rotation of the 
protein on DNA substrate during DNA translocation pow-
ered by ATP hydrolysis. 
5 three sites is necessary for activation of the receptors which 
results in opening of the channel pore allowing passage of 
small cations (Na+, Ca2 +, and K+). P2X7R has received 
particular attention as a potential drug target for its wide-
spread involvement in inflammatory diseases and pivotal 
4.2 Revolution Nanomachines 
All the dsDNA viruses known to date utilize similar 
mechanisms to transport their genome into preformed pro-
tein shells during replication. For example, Bacteriophage 
phi29, HK97, SPPl, P22, and T7 all share a common 
revolution mechanism for dsDNA packaging that employ a 
hexameric ATPase and predominantly dodecameric connec-
10 roles in central nervous system (CNS) pathology [30]. These 
concepts will broaden the therapeutic potential of drugs that 
target multi-subunit channel proteins, including receptor 
heteromer-selective drugs with a lower incidence of side 
effects. They will also help to identify new pharmacological 
15 profiles using cell models that express heteromeric recep-
tors. 
Targeting Homomeric Enzyme for Antibiotics Develop-
ment 
Targeting of key enzymes in essential biosynthesis path-
ways is an important approach for antibiotics development. 
Many key proteins in the fatty acid synthesis pathway and 
nucleotide synthesis pathway are found to be multivalent. 
The highly ordered oligomeric enzymes in biosynthesis 
pathways could be promising targets for developing more 
tor channels for packaging dsDNA. The phi29 DNA pack-
aging motor is composed of three coaxial rings: a dodeca-
meric channel ring and an ASCE hexameric ATPase linked 20 
by a hexameric ring of pRNA (FIG. 4C)[20, 54, 58]. During 
genome packaging, more than 10,000 ATP molecules are 
consumed by the hexameric ATPase as energy source to 
drive the translocation of one copy of the dsDNA genome 
[59]. 
The ASCE superfamily, including FtsK-HerA superfami-
lies and the AAA+ (ATPases associated with diverse cellular 
Activities), is a clade of nanomachines that display a hexa-
meric arrangement[73-76] of subunits. Their biological 
function is to convert chemical energy from ATP into 30 
mechanical motion[20, 29, 77, 78], typically associated with 
conformational changes oftheATPase enzyme [20, 79, 80]. 
25 potent antibacterial drugs. Some examples of developing 
potent drags by targeting multisubunit biocomplexes are 
discussed below. 
FtsK belongs to the ASCE superfamily. It is a multi-
domain protein composed of a C-terminal ATPase domain 
FtsK(C) containing a, ~ and y sub-domains, an N-terminal 35 
membrane-spanning domain FtsK(N) and a 600-amino acid 
linker[81-83]. It is responsible for conjugation between 
bacterial cells and dsDNA bidirectional translocation[84, 
85]. It has been proposed that FtsK subunits acts in a 
sequential manner employing a revolution mechanism to 40 
translocate dsDNA[86, 87]. The crystal structure and elec-
tron microscopy of FtsK(C) demonstrates formation of a 
ring-like hexamer with DNA passing through the hexameric 
ring (FIG. 4D)[87, 88]. 
Fatty acid synthesis is an essential lipogenesis process in 
both Gram-positive and Gram-negative bacteria. A key 
enzyme in the fatty acid biosynthesis pathway is fatty acid 
biosynthesis 1 (FabI), which is a homotetramer complex 
acting as the major enoyl-ACP reductase present in Burk-
holderia pseudomallei (8pm). A recent X-ray structure 
study revealed the binding mode of the inhibitor PT155 with 
the homo-tetrameric BpmFabI [31] (FIG. SA). The substrate 
BpmFabI is a homo-tetramer, one PT155 molecule bound to 
each monomeric subunit has shown significant promise for 
antibacterial drug development[31]. Another example of 
targeting multisubunit biocomplex as drug target is found in 
the guanine nucleotide biosynthesis pathway to control 
parasitic infection. Inosine 5'-monophosphate dehydroge-
nase (IMPDH) is a homo-tetramer enzyme[32](FIG. 5B), 
which plays an important role by catalyzing the oxidation of 
IMP to XMP in guanosine monophosphate (GMP) biosyn-
Targeting Biocomplexes for Developing Potent Drugs 
As illustrated above, drug efficiency follows a power 
function of the stoichiometry of the subunits of the multi-
meric target biocomplex. Targeting biocomplexes with 
higher stoichiometry therefore can lead to the development 
45 thesis[32]. Structural characterization of IMPDH with 
chemical inhibitor drugs indicates that binding to the repeat-
ing units shows a more potent inhibition effect[90]. 
of more potent drugs. Experimentally, approaches targeting 50 
receptor dimers, hetero- and homo-oligomers for drug 
screening open exciting possibilities for drug discovery and 
development[89]. 
Targeting Homomeric Channel Proteins for Drug Devel-
opment 55 
In the history of drug development, one important prop-
erty of most channel protein receptors has been overlooked, 
their stoichiometry. As a matter of fact, many channel 
proteins are expressed as dimers or oligomers on cell 
membrane, including most G-Protein-Coupled Receptors 60 
(GPCR) proteins [89]. Targeting of GPCR hetero- and 
homo-oligomers is generally starting to be considered for 
drug development. Therefore, new models for multisubunit 
protein binding are being developed[89]. Cooperative bind-
ing affinity between ligand and multi subunit targets has been 65 
reported and cooperativity factors were calculated by fitting 
to the Hill equation[23, 89]. 
These examples of successfully targeted homotetramer 
enzymes for potent drug development further proved the 
importance of the stoichiometry of target homo-meric com-
plexes. When applying this method to search enzymes as 
drug targets, it is critical to test whether the stoichiometry of 
the complexes (Z) is > 1, and the number of subunits needed 
to inhibit to block biological function (K) equals 1. 
Targeting Homomeric Drug Transporters for Drug Devel-
opment 
The mechanism of drug transporter, very similar to that of 
the revolution motor, involves entropy induced transitions 
by ATP. High stoichiometry of the target complex is a key 
consideration in drug efficiency. Targeting multidrug efflux 
transporters with high stoichiometry has a better chance to 
develop drugs for treating multi-drug resistant disease. The 
structure of bacterial multidrug efflux transporter AcrB is 
composed of three alpha-helix subunits, that connect to form 
a funnel around a central cavity (FIG. 5C)[91]. The multi-
drug exporter MexB from Pseudomonas aeruginosa also 
forms a homotrimer (FIG. 5D)[92]. Pyridopyrimidine 
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derivatives have been reported to be promising drugs to treat 
multidrug resistant pathogens by specific inhibition of the 
homotrimeric AcrB and MexB transporters[ll 7]. The struc-
tural architecture of ABC transporters consists minimally of 
two TMDs and two NBDs. These four individual polypep-
tide chains combine to form a full transporter such as in the 
E. coli BtuCD[93]. Although the stoichiometry of the het-
erodimer is not very high, the stoichiometry of ATP per 
transporter is high. It is involved in the uptake of vitamin 
B12. The TMDs of ModBC-A and MalFGK2-E have six 
helices per subunit. These unique structural features can be 
used in target considerations. 
Conclusion and Future Perspective 
Targeting functional biological units with higher stoi-
chiometries allows for higher inhibition efficiencies. The 
inhibition efficacy follows a power law with respect to the 
subunit copy number when targeting multimeric biocom-
plex, compared to a linear effect of the drug-target binding 
affinity when targeting a single-subunit substrate. This new 
concept outlined herein suggests that potent drugs can be 
developed by targeting biocomplexes with high stoichiom-
etries with the potential of complete inhibition of the targets 
activity. Possibly, this method can further be applied to guide 
development of dominant negative proteins for potent gene 
therapy, which can be incorporated into a multimeric protein 
nanomachine and results in a change of its activity [94]. 
Since bio-motors share certain common structural and 
operational mechanisms across viruses, bacteria, and cells, 
this approach has general applicability in drug development. 
36 
Hui's (Pascal's) Triangle (also known as binomial distribu-
tion) (FIG. 1), as shown in equation 2. 
It was observed that inhibition efficiency of virus repli-
cation correlates with the stoichiometry of the drug target. 
5 The inhibition efficacy follows a power law behavior where 
the percentage of uninhibited biocomplexes equals q2 (see 
equation 2). For a system with fixed q and K values, the 
inhibition efficiency thus depends on Z, the number of 
subunits within the target biocomplex or bio-machine. This 
10 hypothesis is supported by empirical data that a target with 
ten-thousand-subunits shows higher inhibition effect than a 
target with six subunits, which in tum shows higher inhibi-
tion than a single-subunit target (FIG. 3). The unconven-
15 tional hypothesis described in this article for the develop-
ment of potent drugs with power function behavior with 
respect to the target stoichiometry can be foreign or even 
outlandish to the main force of the pharmaceutical field. The 
approach of developing highly potent drugs through target-
20 ing of protein, RNA or other macromolecule complexes with 
high stoichiometry has never been reported due to chal-
lenges to prove the concept. 
Traditionally, it is almost impossible to prove this concept 
by comparing efficacies of two drugs where one of them 
25 targets a biocomplex with multiple subunits. When reporting 
the efficiency of this new approach, it is very difficult to 
distinguish essentiality of the two targets in biological 
function, it is also very challenging to compare the binding 
affinity of two different drugs to two different targets. For 
30 instance, if two drugs target two stoichiometrically different 
complexes, it becomes extremely difficult to prove whether 
the difference in drug efficiency is due to differences in their 
target binding affinity or essential level of the target in the 
Living systems contain many elegant arrays, motors and 
nanomachines that are composed of multiple identical sub-
units. As reported here, these homomeric biocomplexes can 
serve as potent drug targets. For example, most members of 
the ASCE family are hexamers[20, 95-99]. As these 35 
machines are common among living systems, specificity and 
toxicity need to be considered. In the development of 
anti-bacterial and anti-viral drugs, specificity and toxicity is 
not problematic since the target biocomplexes differ from 
those found in human cells and thus all targets are intended 
biological organism. 
The mechanism of drug inhibition mainly relies on block-
ing an essential biological target element from functioning. 
The target elements can be monomers or a complex of 
multiple homosubunits; such as the biomotors of the hexa-
meric ASCE superfamily[20, 38]. Conventional drugs are 
40 designed to target a single subunit molecule to inhibit 
pathogenesis, such as an enzyme or a structural protein of a 
virus. The key in designing potent drugs is to target multi-
subunit biological motors, machines, or complexes with Z> 1 
and K=l, where Z is the stoichiometry of the complex and 
to be killed nonexclusively. In the development of anti-
cancer drugs, mutations in multiple-subunit biocomplexes of 
cancer cell will present ideal targets for potent drug devel-
opment. 
Expert Opinion 
Drug discovery is a multidisciplinary science including 
the fields of medicine, biotechnology and pharmacology. 
Aiming to find a method for developing drugs with ultra-
high potency, much effort has been placed in the screening 
of new drug compounds, uncovering of new drug targets, 
and illumination of functional pathways, but little attention 
has been paid to the exploration of new methods for the 
design and development of more efficient drugs. Here we 
propose that the inhibition efficiency of a given drug 
depends on the stoichiometry of the biocomplex or bio-
machine that serves as drug target. Here the notion of 
"stoichiometry" differs from the conventional concept in 
drug development. Conventionally, stoichiometry refers to 
the number of drug molecules bound to each substrate or cell 
membrane. In the current study stoichiometry refers to the 
number of identical subunits that the target biocomplex is 
composed of. Phi29 viral components with a series of 
variable but known stoichiometries were evaluated as mock 
drug targets to test the hypothesis. Both in vitro and in vivo 
virion assembly assays were employed to compare inhibi-
tion efficiencies for targets with differing subunit stoichiom-
etries. Viral inhibition efficiency was analyzed with Yang 
45 K is the number of drugged subunit that are required in order 
to block the function of the entire complex. Similarly, in a 
series circuit Christmas decorative light chain, one broken 
light bulb will tum off the entire lighting system. 
In most, if not all, multi-subunit biological systems, 
50 sequential coordination or cooperative action mechanisms 
are utilized, thus, K equals 1. Drug inhibition depends on the 
ratio of drugged to the non-drugged complex. For K=l, and 
Z> 1, inhibition efficacy follows a power function with 
respect to Z, leading to an increased potency of the drug 
55 since inhibition of any subunit results in complete inhibition 
of activity. For a drug designed to target a single-subunit 
molecule at targeting efficiency p, the fraction ofundrugged 
target molecules q that will remain active is 1-p. In this 
situation, the inhibition efficiency is proportional to the 
60 substrate targeting efficiency p and the inhibition efficacy is 
of the first order of p. Sequential action or cooperativity in 
multi-subunit complexes has widely been reported in bio-
logical systems[39-41]. Drugs targeting a complex with 
multiple subunits can inhibit the complex activity if any 
65 homosubunit of the target is inactivated. Thus, if the copy 
number of this cooperative complex is Z> 1, and the least 
number of blocked subunit to inhibit complex activity (K) is 
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1, the fraction of uninhibited biocomplexes is q2 , and the 
inhibition efficiency is l-q2 , where 1-q is the portion of 
drugged subunits. 
38 
The binomial distribution analysis allows prediction of 
the inhibition efficiencies. For example, in targeting a six- 5 
subunit biocomplex with K=l, the inhibition efficiency is 
determined by drug binding to any one of the six homo sub-
units. Therefore, the probability of inhibiting any subunit at 
expressed or directly introduced, into a highly multimeric 
complex that is identified as the target unit. For purposes of 
serving as a small molecule drug target, a multimeric 
complex might be identified, such that binding of one drug 
molecule to any one binding site on the complex will 
inactivate the whole complex. The fact that the complex 
composed of Z subunits holding one drugged subunit will 
only come into play as the drug concentration is at the high 
end. However, if the strategy was to express a dominant 
random position is 
l-q6 
1-q 
times higher than inhibiting a monomer substrate. With this 
new elucidation and understanding of the concepts behind 
targeting of cooperative multi-homosubunit complexes, a 
new generation of potent drugs may emerge in the near 
future. 
Our discovery is an approach, not a drug. This approach 
will have general impact in the development of drugs for 
many diseases such as cancer, viral or bacterial infections. In 
living systems, biological machines or complexes with high 
stoichiometry and operated by sequential cooperative action 
or coordination with Z> 1 and K = 1 are ubiquitous. This class 
of biological machines is involved in many aspects of 
crucial cellular processes to the survival of viruses, bacteria, 
and eukaryotic cells. For example, multi-subunit biomotors 
are involved in chaperon, ATPase, ATP synthase, cell mito-
sis, bacterial binary fission, DNA replication, DNA repair, 
homologous recombination, Holliday junction resolution, 
nuclear pore transportation, RNA transcription, drug trans-
porters, muscle contraction, viral genome packaging, as well 
as motion, trafficking, and exportation of cellular compo-
nents. These systems use a sequential mechanism similar to 
the serial circuit of the Christmas decoration lighting chain. 
Thus, our approach will have broad application in drug 
development in many biological systems. Drugs targeting to 
these motors will be highly efficient. 
Biomotors belonging to the multi-subunit ATPase are 
widely spread in organisms, including bacteria, viruses and 
cancer cells. Successful implementation of this new meth-
odology will lead to the development of the next generation 
10 
negative protein, as has been done in recent cardiac gene 
therapy with dominant negative phospholamban[94], a high 
inhibition efficacy will achieve. The greater the value of Z 
the more the effect of the dominant negative protein subunit 
or mutant subunit will be achieved. 
Another possibility is the use of homomeric drug trans-
15 porters [113, 114] as drug targets (see section 5.3). The 
mechanism of drug transporters is very similar to that of the 
revolution motor featuring an entropy transition induced by 
ATP. High stoichiometry of target complex is a key consid-
eration for achieving high drug efficiency. Targeting multi-
20 drug efflux transporters with high stoichiometry has a better 
chance to develop drugs for treating multi-drug resistant 
disease. 
While the hypothesis behind this method might theoreti-
cally seem challenging, elucidation of the mechanism 
25 should greatly facilitate application of this approach. Two 
factors are essential for drugs development: efficiency and 
specificity. The strategy described herein focuses on drug 
efficiency, while specificity is similar to the general consid-
eration in the development of chemicals and drugs. Never-
30 theless, design of potent drugs to common machines or 
general targets is still possible. For example, if an oncogenic 
mutant hexameric ATPase is found in one specific type of 
cancer cells, drugs targeting to this mutation of the altered 
ATPase will not only be highly efficient but also specific. 
Using multisubunit homomeric complexes such as AAA+ 
35 family ATPase, biomotors or drug transporters with high 
stoichiometry could lead to development of highly potent 
drugs. 
Most multisubunit complexes work in a sequential and 
cooperative manner, that is K=l, which is the key for these 
40 complexes to be used as target for potent drug development. 
Bacterial virus Phi29 DNA packing motor contains many 
multisubunit components with different stoichiometries; it is 
a good model to elucidate the concept of stoichiometry in 
drug development. 
of potent drugs. In fact the first drug approved to treat 45 
multidrug-resistant tuberculosis, bedaquiline [ 4], is acting 
Multisubunit nanocomplexes such as biomotors or 
ATPase are widely spread in nature. Thus, the method 
should have broad application in the development of new 
drugs. For example, the use of ATP synthase as drug target 
has led to the development of a new drug for treating 
50 multidrug resistant tuberculosis. 
on the ATP synthase which is a multisubunit biomotor 
[100-111]. Treating multidrug-resistant tuberculosis had 
been very challenging previously. Although this drug's 
inventors were not aware of the concept of targeting mul-
tisubunit complexes for potent drug development, the suc-
cess in this drug conquering the tough Mycobacterium 
tuberculosis organism supports the concept of using the 
multisubunit complex as a potent drug target. Cancer or 
bacterial mutant multi-subunit ATPase can be used as target. 55 
The drug developers can simply check the published litera-
ture and identify a multi-subunit machine as the drug target. 
For cancer treatment, it is to find a multi-subunit machine 
with mutation. 
The concept of K = 1 for high efficiency inhibition may be 60 
impactful in gene or protein therapy. By introducing the 
dominant negative protein[94] or inactive mutant protein 
into the cell, either by intracellular expression or direct 
introduction of proteins, which resembles the above illus-
trated approach and mechanism used for phi29 DNA pack- 65 
aging motor systems [13, 14, 45, 112](FIG. 9). This involves 




To find a method for developing potent drugs and to prove 
a hypothesis that drug inhibition potency depends on the 
stoichiometry of the targeted biocomplex. 
Methods: 
Phi29 DNA-packaging motor components were used to 
test this model for different stoichiometries. Viron assembly 
efficiency was assayed with Yang Hui's Triangle: 
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where Z=stoichiometry, M=drugged subunits in each bio-
complex, p and q represent the fraction of drugged and 
non-drugged subunits in the population. 
Results: 
40 
higher potency by acting on multiple targets. This involves 
identifying multiple targets that when treated leads to a 
synergetic effect and optimizing the design of multi-target 
ligands. 
Inhibition efficiency follows a power function. When 5 
number of drugged subunits to block the function of the 
biocomplex K=l, the fraction of uninhibited biocomplex 
equals q2 • Thus, stoichiometry has a multiplicative effect on 
inhibition. Targets with a thousand subunits showed the 
highest inhibition effect, followed by those with six and a 
single subunit. Complete inhibition of virus replication was 
found when Z=6. 
The approach of developing highly potent drugs through 
targeting of protein or RNA complexes with high stoichi-
ometry has never been reported due to challenges in com-
paring efficacies of two drugs that can be confused by target 
essentiality with binding affinity. For instance, if two drugs 
10 target two stoichiometrically different targets, it becomes 
extremely difficult to prove whether the difference in drug 
efficiency is due to differences in their target binding affinity 
or essential level in the growth of the biological organism. 
Conclusion: 
Drug inhibition potency depends on the stoichiometry of 
the targeted components of the biocomplex or nano-ma-
chine. The inhibition effect follows a power function of the 
stoichiometry of the target biocomplex. 
Introduction 
15 
In order to quantify effects from targeting biocomplexes of 
different stoichiometry, a well-studied multicomponent sys-
tem is required that allows empirical comparison of func-
tional inhibition of individual components that are com-
posed of different number of subunits. 
An example of one nanobiomachine is the dsDNA trans-
location motor, for which the ATPase protein is a pivotal 
component that assembles into a hexameric ring structure 
and translates the action of ATP binding and hydrolysis into 
mechanical motion to translocate DNA physically. The DNA 
Bacteria, viruses and cells contain biocomplexes and 
nanomachines composed of multiple subunits, such as bio- 20 
motors, pumps, exosomes, valves, membrane pores, chap-
eronins, PCNA, ATPase, and tubes. From a nanobiotechno-
logical standpoint, these nanomachines can be used and 
converted to build sophisticated nano-devices including 
molecular sensors, patterned arrays, actuators, chips, micro-
electromechanical systems (MEMS), molecular sorters, 
single pore DNA sequencing apparatus or other revolution-
ary electronic and optical devices. From a pharmaceutical 
standpoint, these multi-subunit biocomplexes or nanoma-
chines have a potential for use as drug targets for therapeu-
tics, as well as diagnostic applications such as pathogen 
detection, disease diagnosis, drug delivery, and treatment of 
diseases. In the ASCE (Additional Strand Catalytic E) 
family including the AAA+(ATPases Associated with 
diverse cellular Activities) and the FtsK-HerA superfamily 
25 packaging motor of bacteriophage phi29 (FIG. 12A) is 
composed of three essential co-axial rings: 1) a dodecameric 
connector ring located at the vertex of the viral procapsid; 2) 
a hexameric packaging RNA (pRNA) ring (FIG. 12A, B) 
bound to the N-terminus of the connector, and 3) a hexam-
30 eric ring of ATPase gp16 attached to the helical region of 
pRNA, powered through the hydrolysis of ATP resulting in 
DNA packaging. The use ofYang Hui's Triangle or binomial 
distribution to determine the stoichiometry of the pRNA was 
first reported in 1997. The use of similar mathematical 
35 methods to determine the stoichiometry of the protein sub-
units has also been reported more recently. The copy number 
of ATP molecules required to package one full phi29 
genomic dsDNA was predicted to be 10000. It has recently 
been shown that this hexameric motor uses a revolution 
in bacteria, viruses and cells, there are nanomotors that 
perform a wide range of functions critical to chromosome 
segregation, bacterial binary fission, DNA/RNA and cell 
component transportation, membrane sorting, cellular reor-
ganization, cell division, RNA transcription, as well as DNA 
replication, riding, repair, and recombination. One of the 
directions of NIH Roadmap is to utilize these cellular 
nanomachines and biocomplexes for biomedical applica-
tions. 
Acquired drug resistance has become a major reason for 
failure treatment of a range of diseases, i.e., the chemo-
therapy for cancer, bacterial or viral infections. Drug resis-
tance of cancer has escalated and has partially contributed to 
the -600,000 deaths in the USA in 2012. HIV drug resis-
tance has also become a major issue. Many common patho-
gens have become resistant to current drug treatments, with 
new infectious diseases on the rise. The use of multidrug-
resistant agents in biological weapons has created a previ-
ously unrealized challenge. Thus, there is a need to develop 
new treatment strategies to combat drug resistance with new 
drug development methods. 
40 mechanism without rotation to translocate its genomic 
DNA. 
In this report, we hypothesize that the inhibitory efficiency 
of a drug is related to the stoichiometry of its targeted 
biocomplex; the higher the stoichiometry of the target com-
45 plex, the more efficient the drug. This can lead to the 
development of potent therapeutics against high-stoichio-
metric biomachines or biocomplexes as drug targets. We 
proved this hypothesis by using a mutant subunit as the 
drugged inactive target to calculate the theoretical inhibition 
50 efficiency via binomial distribution, and compared with 
experimental data from a defined in vitro viral assembly 
system. Since biomotors share certain common structures 
and operation mechanisms, the approach in drug develop-
ment reported here should have general applications espe-
55 cially in developing new generations of drugs for combating 
the rising acquired drug resistance in viruses, bacteria, and 
The first FDA-approved drug to treat multidrug-resistant 
tuberculosis, bedaquiline, follows a new mechanism of 
inhibiting the bacterial ATP synthase of M. tuberculosis and 
other mycobacterial species, but had little activity against 60 
other bacteria. To combat multidrug resistance in cancer, 
several approaches have been explored. One method is to 
target components that are highly important for the growth 
cancers. 
Materials and Methods 
Preparation of Mutant Genomic dsDNA 
Phi29 genomic DNA-gp3 was purified from B. subtilis 
SpoA12 cells by CsCl gradient ultracentrifugation as 
described previously. Mutant dsDNA was prepared by 
digesting the phi29 genomic dsDNA with EcoRl restriction 
enzyme in fast digest buffer (Fermentas) at 37° C. for 1 hour 
followed by ethanol precipitation. The mutant DNA was 
tested by 1 % agarose gel electrophoresis, stained by 
ethidium bromide (Sigma) and imaged by Typhoon (GE). 
of the biological entity. Another approach uses nano-drug 
delivery carriers that are expected to enhance the binding 65 
efficiency of drugs to cancer cells, or cocktail therapy. A 
third approach is to develop new combinational drugs with 
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Preparation of Mutant pRNA 
Wild-type phi29 pRNA and inactive mutant as drugged 
pRNA were prepared by in vitro transcription. In the inactive 
mutant pRNA, the first four bases "UUCA" (SEQ ID NO: 
11) located at the 5' end were mutated to "GGGG" (SEQ ID 5 
NO: 11). Bg!II digested plasmid pRT71 was used as DNA 
template in the PCR reaction for both RNAs. Oligonucle-
otide 5'-TAA TAC GAC TCA CTA TAG GGG TGG TAC-3' 
(SEQ ID NO: 12) and 5'-TTA TCAAAG TAG CGT GCA 
C-3' (SEQ ID NO: 13) were used as primers for mutant 10 
pRNA. RN As were then transcribed by T7 RNA polymerase 
using double-stranded DNA generated from PCR, as 
described before. The RNA from in vitro transcription was 
further purified by 8 M urea 8% polyacrylamide gel elec-
15 
trophoresis as described previously. 
Preparation of Mutant ATPase Gp16 
The purification of wild-type gp16 has been described 
previously. The walker B mutant gp16 was constructed by 
introducing mutations in the gp16 gene. The amino acid 20 
residues D255 and E256 in walker B motif of gp16 were 
mutated to E255 and D256, respectively. The mutation was 
introduced with the Stratagene Quick Change site-directed 
mutagenesis kit using appropriate primers. The expression 
and purification of protein were carried out followed a 25 
published procedure. 
Antisense Oligonucleotides 
Antisense oligonucleotides P3 and P15 were designed to 
be reversely complementary to different regions on the 
pRNA molecule and chemically synthesized by IDT. P3 30 
oligo (5'-TTGCCATGATTGACAAC-3' (SEQ ID NO: 14)) 
targets the region of 83-99 nucleotides at the 3'end of pRNA. 
P15 oligo (5'-AAGTACCGTACCATTGA (SEQ ID NO: 
15)) targets the region of 1-17 nucleotides at the 5'end of 
pRNA. PS oligo (5'-TAATACGACTCAC- 35 
TATAGGGGTGGTAC-3' (SEQ ID NO: 16)) was designed 
as a non-targeting control in the test. 1 µl of individual oligos 
at 100 µM were mixed with 1 µl of pRNA at 4 µM and 
dialyzed on a 0.025 µm type VS filter membrane (Millipore 
Corp) against TBE buffer (89 mM Tris-HCl, pH 8.3, 89 mM 40 
boric acid, 2.5 mM EDTA) at room temperature for 15 min. 
The purified RNA complex was used for in vitro phi29 
assembly assay. 
In Vitro Phi29 Assembly Assay 
Purified components were subjected to in vitro viral 45 
assembly assay as described previously. Briefly, 10 µg of 
purified procapsids were mixed with 100 ng of pRNA in 5 
µl ofreaction buffer (10 mMATP, 6 mM 2-mercaptoethanol, 
and 3 mM spermidine in TMS buffer) at room temperature 
for 30 min. Purified DNA-gp3 and gp16 were then added 50 
and the reaction mixture was incubated at room temperature 
for one hour to initiate DNA packaging. Finally, the DNA 
filled procapsids were incubated with 10 µl of gpS.5-9 
extract from E. coli containing plasmid pARgpS.5-9 and 20 
µl of gpl 1-14 extract from E. coli to complete the infectious 55 
phage assembly. 
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In Vivo Viral Assembly Assay 
Plasmid pRBwtRNA containing the pRNA coding 
sequence under T7 promoter was constructed by ligating the 
fragment coding pRNA sequence and T7 promoter into 
pRB381-L550 vector (modified and kindly provided by M. 
Wang and H. Zalkin) following a previously described 
method. Plasmid pRBmutRNA contained mutant pRNA 
under its natural promoter PEI sequence, and the mutation 
was changing sequence 5'UUGA-3' (SEQ ID NO: 17) at its 
3'end to 5'GGGG-3'(SEQ ID NO: 18). The DNA fragments 
coding mutant pRNA sequence and PEI sequence were 
prepared by PCR as described previously; and digested with 
HindIII-Bg!II restriction enzyme. The mutant pRNA 
sequence coding fragment was further ligated with a 6.0 kb 
fragment from pRB381-L550 that was digested with HindIII 
and partially digested with Bg!II. 
The plasmids pRBmutRNA, pRBmutRNA, and pRB381-
L550 were transformed into B. subtilis cells following 
methods described previously. The B. subtilis cells harbor-
ing transformed plasmids were incubated in 416 medium 
with 10 mg/ml of neomycin for 3 hours at 3 7° C. and then 
plated onto LB-neomycin (10 mg/ml) plates for plaque 
formation analysis. 
Results 
The Definition of "Stoichiometry". 
The definition of the stoichiometry in this report is 
different from conventional definition of stoichiometry used 
to evaluate drug efficiency. Conventionally the concept of 
stoichiometry refers to the number of a drug binding to each 
target molecule, which is also known as Bmax· In this study 
the definition of stoichiometry refers to the copy number of 
subunit within a biocomplex or the nanomachine that serves 
as drug target. 
The Definition of "K Value", and K=l is One Key for 
Ultra-High Inhibition Efficacy 
Suppose a biocomplex drug target contains Z copies of 
subunits, then K is the copy number (KsZ) of drugged 
subunits required to inhibit the function of the complex or 
the nanomachine. As an analogy to the difference between 
the parallel circuit and the serial circuit, when the Christmas 
lights are arranged in a parallel circuit, any light bulbs that 
are burnt out will not affect other bulbs. But in a serial 
circuit, any one light bulb that is broken will stop the entire 
lighting system, which is K=l. Thus, the K value is the key 
to the probability of inactive nanomachines or biocomplexes 
by combination and permutation of all subunits. K equals 1 
is critical for such ultra-high inhibition effect. The founda-
tion of the approach in this report is the difference in 
probability of inhibited biocomplexes in systems of different 
K values with combination and permutation algorithms. 
Biological systems display complicated reactions. Many 
reactions involve multiple subunits to work cooperatively 
sequentially or precessively to accomplish one essential 
biological function. Single assembly pathways have been 
reported in the viral assembly system. In most cases of the 
sequential, cooperative, and processive action, inactivation 
of any one, not necessary all, of the subunits will result in 
inhibition of its function, thus K=l. Drug synergism was 
utilized in multi-target drug therapy; in short, a drug com-
bination can simultaneously act on multiple targets in dis-
The newly assembled infectious viruses were plated with 
inoculated B. subtilis bacteria su+44 cells onto a half LB 
plate covered with top agar. After 12 hour incubation at 37° 
C., the viral assembly efficiency (plaque-forming unit, PFU) 
was calculated by counting the formed plaque numbers. 
Mixing different ratios of mutant with wild-type compo-
nents, while keeping all other components the same, the 
viral assembly efficiency (PFU) versus ratio of mutant 
components gave an empirical curve for vial assembly 
inhibition assay, and it was compared with theoretical curves 
from the binomial distribution equation. 
60 ease networks to produce a synergistic effect. However, our 
design reported here is unique from the conventional syn-
ergistic approach. We suggest that using multi-subunit bio-
complexes as drug target could lead to development of 
ultra-high potent drugs. In a conventional six-component 
65 system, for example one drug is designed to target compo-
nent #3 to stop the entire system, since the drug can only 
target component #3, the condition fits the model of Z= 1 and 
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K=l. Thus, the inhibition efficiency and substrate targeting 
efficiency (p) of drug will be in linear relationship. However, 
in the system in this report, the entire system will be blocked 
when drug targets any subunit of a hexamer, which is Z=6 
and K=l. Thus the probability of remaining undrugged 5 
targets will be q6 , where q represents the fraction of untar-
geted hexamer subunits; in other words, the drug inhibition 
efficiency will be l-q6 , which increases following a power 
function compared to the linear for conventional mono-
subunit approaches. 10 
Assuming that at least K copies of drugged subunits were 
needed to deactivate the nanomachine or biocomplex, the 
probability of functional biocomplexes in the presence of 
various ratios of inhibited and wild-type subunits could be 
15 
predicted from equation 2. When K=l, it implies that drug 
binding to one subunit will inactivate the subunit, and one 
drugged subunit per multi-subunit complex is sufficient to 
inhibit the overall function of the complex. The inhibition 
efficiency by drugs targeting multi-subunit biocomplexes 20 
with stoichiometry of Z will equal l-q2 , as shown in table 
2. An example for such a probability calculation when Z=6 
and K=l is as follows: since it was assumed that 6 (Z=6) 
copies of subunits per element were required for function 
and one drugged subunit (K=l) was sufficient to block its 25 
activity, all elements possessing 1 to 5 copies of drugged 
subunits would be non-functional (FIG. lC). Only those 
complexes possessing 6 copies of normal subunits will be 
functional. The chance for a complex containing 6 copies of 
unaffected subunits in a population is q6 and the inhibition 30 
efficiency will be l-q6 • 
Rationale Behind Selection of Multi-Subunit Biocom-
plexes as Efficient Drug Targets 
44 
When the target element is a monomer containing only 
one subunit, the inhibition efficiency can be calculated 
through a binomial distribution ( equation 1 ), where p and q 
are the fractions of drugged (substrate targeting efficiency) 
and undrugged (normal active elements) subunits, respec-
tively (p+q=l). 
However, when the target element contains multiple sub-
units, a high order binomial distribution (equation 2) is 
applied to calculate the drug inhibition effect by finding the 
ratio of resulted active and inactive complexes, where Z 
represents the total number of subunits (the stoichiometry) 
in one biocomplex and M represents the number of drugged 
subunits in one biocomplex. 
(2) 
Note that the binomial distribution as set forth in equation 
2 may also be expressed as follows: 
~(z)M.2-M ~( Z! )M.2-M U M p ~ = U M!(Z-M)! p ~ 
M=O M=O 
Computational results based on the binomial equation are set 
forth herein. The context of the results governs which form 
of the equation is used. 
For example, if Z is 3, the probability of all combinations 
of drugged subunits (M) and undrugged subunits (N; Mechanisms for drug inhibition of organism growth are to 
block or stop an essential biological element from function-
ing. When a drug is designed to target the subunit of a 
complex with targeting efficiency p, a fraction of subunits 
will not interact with the drug (a percentile given as q, 
p+q=l) and will remain active and exert their function 
properly. Some biological elements are monomers contain-
ing only one subunit, while other biological elements, such 
as the bin-motors of hexameric AAA+ family, consist of 
multiple-subunits. Conventional drugs are designed to 
inhibit pathogenesis through targeting of a single subunit 
molecule, such as an enzyme or a structural protein of a 
virus. In this situation, the inhibition efficiency is propor-
tional to the substrate targeting efficiency p and the effect is 
proportional to the first order of p. As described above, in 
most cases of sequential action or cooperatives in multiple 
subunit complexes, inactivation of one, not all, of the 
subunits will result in inhibition of its function. Thus, if 
complexes containing Z copies of subunits exercise their 
function in a sequential and cooperative way, then K=l, and 
the fraction of the uninhibited active biocomplex will be q2 , 
35 M+N=Z) in a given biocomplex entity can be determined by 
the expansion of equation 2: (p+q)3=p3 +3p2q+3pq2 +q3 =1. 
That is, the probability of a complex element possessing 
three copies of drugged subunits in the population isp3 , two 
copies of drugged and one copy of undrugged or wild-type 
subunit is 3p2 q, one copy of drugged and two copies of 
40 2 
undrugged subunits is 3pq , and three copies of undrugged 
subunits is q3 • Assuming there were 70% (p=0.7) of subunits 
inactivated by bound drugs, and 30% (q=0.3) unaffected 
subunits in the population, then the percentage of elements 
possessing at least two copies of normal subunits would be 
45 the sum of those possessing one copy of drugged and two 
copies of undrugged wild-type subunits, 3pq2 , and those 
possessing three copies of native subunits is q3 • That is 
3pq2 +q3=3(0.7)(0.3)+(0.3)3=0.216=21.6%. In another 
example, if one complex contains 6 subunits, and 5 out of 
50 the 6 subunits need to remain uninhibited in order to be 
a higher order with regards to the stoichiometry. The inhi- 55 
bition proportion will equal l-q2 . 
In this investigation, a well-defined in vitro phi29 viral 
assembly system was used to represent a multi-subunit 
nano-machine target, with the mutant component represent-
ing a target component that have been inactivated by an 60 
effective drug. Then, the inhibition efficiencies by targeting 
different elements of the phi29 DNA packaging motor with 
different stoichiometry were compared. The viral assembly 
competition assays combined with binomial distribution 
analysis illustrated the concept that drug targeting functional 65 
biological complexes of a higher-stoichiometry has a higher 
efficiency than drug acting on a single subunit target. 
biologically functional, the active complex ratio in the 
population will be the sum of: 1) the probability of each 
element containing 5 undrugged subunits, and 2) the prob-
ability of each element containing 6 undrugged subunits. 
The probability X in the population displaying a certain 
combination of undrugged versus drugged subunits can be 
predicted by a binomial distribution, as shown in equation 2. 
Table 1 shows the probability of a given element with M 
drugged and N undrugged subunits at increasing percentages 
of drugged subunits in the population, considering that the 
total subunits in one element (Z) is 3 or 12. The formula, 
Z! M N 
M!N!p q 
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(from equation 2) was used to calculate each combination 
probability value, the coefficient 
Z! 
M!N! 
in this equation can also be calculated using Yang Hui 
Triangle, which is also called Pascal's Triangle, or binomial 
distribution (FIG. 12B). 
In Vitro Virus Assembly System Used for Testing the 
Hypothesis 
The highly sensitive in vitro phi29 assembly system was 
used to determine the inhibition efficiency of drugs targeting 
multi-subunit complexes. Bacteriophage phi29 DNA pack-
aging motor contains one copy of genomic dsDNA, 6 copies 
of packaging RNA, 6 copies of ATPase protein gp16 and 
more than 10000 copies of ATP. The stoichiometry of RNA 
46 
was constructed by mutating 4 nucleotide sequences at the 
5'end region of pRNA (FIG. 14A, lower panel), which has 
been shown to compete with wild-type pRNA for procapsid 
binding, but was found to be deficient in allowing DNA 
5 packaging to occur. The theoretical curves generated using 
the expansion of binomial distribution equation while total 
subunit number Z is 6 and varying K number from 1 to 6 are 
shown in FIG. 14B. Fitting the empirical data from phage 
assembly efficiency at different ratios of drugged mutant 
10 pRNAs into the theoretical curves, the empirical data fit into 
the theoretical curve of Z=6 and K=l. It suggested that the 
pRNA oligomer ring is composed of six copies of pRNA 
subunits and one subunit of the pRNA multimer blockage is 
sufficient to block the phage assembly activity. Comparing 
15 the empirical curve for viral assembly efficiency against 
different ratios of drugged mutant pRNAs with the wild-type 
pRNA concentration dilution control, addition of drugged 
mutant pRNA showed a much stronger inhibition effect 
(FIG. 3C). 
in phi29 has been proven by extensive studies including 20 
single-molecule studies AFM images (FIG. lD), pRNA 
crystal structure determination (FIG. lE), and mathematical 
studies. The stoichiometry of gpl 6 in phi29 has been proven 
To further prove the concept that drugs targeting biocom-
plex with high stoichiometry causes stronger inhibition 
effect, antisense oligonucleotides which can bind to pRNA 
molecules were designed as mock drugs in the viral assem-
bly assay. The oligonucleotides P15, and P3 were designed by multiple approaches including native gel binding, capil-
lary electrophoresis assays, Hill constant determination, and 
by titration of mutant subunits using binomial distribution. 
Many other AAA+ superfamily members have been found to 
be hexamers as well, such as a red type rubisco activase 
AAA+ protein CbbX (FIG. 12F), MecA-ClpC molecular 
machine (FIG. 12G). The copy number of ATP molecules 
was calculated based on the fact that 6 ATP molecules are 
required to package one pitch of dsDNA with 10.5 basepairs 
(hp), thus 1 ATP is used to package 1.7 bp. The entire phi29 
genome is composed of 19.4 kbp, thus, it is expected that 
more than 10000 ATP molecules are required to package the 
entire phi29 genome. The phi29 DNA nano-motor which 
packages an entire genomic DNA into the procapsid can be 
treated as a disease model for drug inhibition efficiency 
analysis. 
In Vitro Testing of the Hypothesis Using DNA Element 
with Stoichiometry of 1 
The inhibition efficiency of drugs targeting a single sub-
unit substrate was tested by in vitro phi29 assembly inhibi-
tion by mutating the genomic dsDNA (FIG. 13A). Various 
ratios of mutant DNA were mixed with wild-type DNA in in 
vitro viral assembly assays. The empirical curve of viral 
assembly efficiency against drugged mutant DNA ratio fits 
well with the theoretical curve from binomial distribution 
for Z=l and K=l (FIG. 13B). This suggests that when 
designing drug targeting the genomic DNA in phi29 nano-
motor, it is expected to be a first order inhibition response. 
Comparing the in vitro phi29 assembly inhibition, by adding 
drugged mutant DNA, with simply diluting wild-type DNA 
concentration as a control, revealed that the drugged mutant 
DNA didn't cause much difference (FIG. 13C). The results 
showed that the inhibition effect of drugs targeting the 
substrate with stoichiometry of 1 is minimal. 
In Vitro Testing of the Hypothesis Using RNA Elements 
with Stoichiometry of 6 
The pRNA of phi29 contains two domains; a head-loop 
domain essential for procapsid binding and a helix domain 
essential for DNA translocation (FIG. 14A, upper panel). 
The right-hand loop and left-hand loop of two pairing pRNA 
molecules can interact with each other by complementary 
base pairing. Extensive studies have led to the conclusion 
that 6 copies of pRNA form a hexameric ring which binds 
to the procapsid for virus activity. Drugged mutant pRNA 
25 to target the 5'-end and 3'-end regions on pRNA, respec-
tively. It was confirmed that the antisense oligonucleotides 
can be hybridized to pRNA by gel shift assay ( data not 
shown). When mixing the antisense oligonucleotides with 
wild-type pRNA for in vitro phi29 assembly assay, complete 
30 inhibition effects were shown by antisense oligonucleotides 
P15, and P3, but not with the non-targeting control oligo-
nucleotide PS. By mixing the non-targeting oligo PS with 
pRNA, it generated plaques with 4.4xl06 PFU on the plate. 
In Vivo Testing of the Hypothesis Using RNA Elements 
35 with Stoichiometry of 6 
Formation of the hexameric ring of pRNA in the phi29 
dsDNA packaging motor has been discovered through bio-
chemical and structural studies and activity assays. The 
observed high inhibition efficiency by drugged mutant 
40 pRNA on phi29 assembly in vitro was striking. To test 
whether such a high level of inhibition was attainable in 
vivo, pRBmutRNA plasmid expressing a pRNA with 4-base 
mutation at the 3' end (FIG. 15A) was transformed into B. 
subtilis DEi cells. Plasmid pRBwtRNA contained the 
45 pRNA coding sequence but do not express pRNA in B. 
subtilis DEi cells, and vector pRB3Sl-L550 was introduced 
as well as a negative control. The results showed that only 
cells harboring pRBmutRNA plasmid were completely 
resistant to plaque formation by wild-type phi29 virus 
50 infection. Control cells, includingB. subtilis 12Acells alone, 
B. subtilis DEi cells carrying vector pRB3Sl-L550 alone, 
and cells carrying a wild-type pRNA coding sequence but no 
expression plasmid pRBwtRNA were all positive for plaque 
fin (nation (FIG. 15B). The ability of mutant pRNAs gen-
55 erated in cells by plasmid pRBmutRNA completely inhib-
ited plaque formation indicated that hexameric pRNA in 
DNA packaging nano-motor may be a potential target for 
developing potent antiviral agents. 
In Vitro Testing of the Hypothesis Using theATPase with 
60 Stoichiometry of 6 
Hexameric folding of ATPase gp16 protein in the phi29 
dsDNA packaging motor has been discovered. The hexam-
eric gp16 protein complex functions as ATPase like many 
other AAA+ superfamily members. ATP binding to one 
65 subunit of gpl 6 stimulates the ATPase to change its confor-
mation from having a lower affinity to one having a higher 
affinity for dsDNA. 
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Determination of gp16 stoichiometry was carried out by 
in vitro phage assembly assay and based on the binomial 
distribution of wild-type and Walker B mutant gp16. Dif-
ferent ratios of drugged Walker B mutant gp16 were mixed 
with undrugged gp16 to test the inhibition efficiency of gp16 5 
mutation on phi29 DNA packaging motor. Assuming K 
equals 1 and the total copy number of gp16 (Z) is between 
1 and 12, twelve theoretical curves for the production of 
phi29 virion against the ratio of the Walker B mutant 
corresponding to the stoichiometry (Z) of 1 to 12 were 10 
generated according to equation 2. The empirical data nearly 
perfectly overlapped the theoretical curve of Z=6, K = 1. This 
data suggested that the ATPase gpl 6 components of phi29 
DNA packaging motor have a stoichiometry of six, and only 
one copy of the drugged gp16 can block the phi29 motor 15 
function. Comparing the inhibition effect of adding mutant 
gp16 with wild-type gp16 at different concentrations, it 
showed that adding mutant gp16 had a much stronger 
inhibition effect than the wild-type gp16 concentration dilu-
tion control (FIG. 16A). Comparing the inhibition effect of 20 
mutation on hexameric gp16 to the effect of mutation on 
single subunit target DNA, the gp16 mutation displayed a 
much stronger inhibition effect on virus assembly than the 
same ratio of DNA mutation, indicating the hexameric 
ATPase protein complex of virus assembly system should 25 
also be an efficient target for generating new anti-virus drugs 
with high potency. 
In Vitro Testing of the Hypothesis Using ATP with Stoi-
chiometry of More than 10000 
It has been reported that 6 ATP molecules are required to 30 
package one pitch of dsDNA with 10.5 bp [90], thus 1 ATP 
48 
y-S-ATP almost completely inhibited the viral assembly, 
indicating the higher the stoichiometry, the stronger the 
inhibition efficacy. 
Mathematical Reasoning for the Increase of Inhibition 
Efficacy 
Using a biological complex with higher stoichiometry as 
drug target will substantially reduce the proportion of non-
inhibited complex. For K=l, the proportion of non-inhibited 
complex is q2 . Table 3 compares the proportion of non-
inhibited complex from two populations with Z=6 and Z=l, 
respectively, with varied substrate targeting efficiency (p) 
when K=l. For example, when q=0.4, the proportion of 
non-inhibited complex is q2 =0.4 1=0.4 for Z=l K=l. There-
fore, only 1-0.4=60% of complex is inhibited. In contrast, 
for Z=6, K=l, the proportion of non-inhibited complex is 
q2 =0.46=0.0041. Therefore, 1-0.0041=99.59% of complex 
is inhibited. The ratio of the proportions of non-inhibited 
complex equals 0.0041/0.4=0.0102, indicating a 
1/0.0102=98-fold decrease in the proportion of non-inhib-
ited complex. One more example is to use the drug targeting 
efficiency p=0.9 to compare the inhibition efficiency 
between two groups with Z=6 and Z=l. For Z=6, K=l, the 
proportion of inhibited complex is l-q2 =1-0.l 6=0.999999. 
The proportion of non-inhibited complex is q2 =0.1 6=1E-6. 
For Z=l, K=l, the proportion of inhibited complex is 
l-q2 =1-0.1 =0.9. The proportion of non-inhibited complex is 
q2 =0.1. The ratio of inhibition efficiency equals to lE-6/ 
0.l=lE-5, indicating a 10000-fold increase in inhibition 
efficiency (Table 3). 
The equation displays inhibitory effect with a power 
function of stoichiometry since when K = 1, the percentage of 
uninhibited biocomplexes in the population equal to q2 • 
Since (P+q)=l, thus qsl, thus the larger the Z, the smaller 
the value of q2 That is to say, the higher the stoichiometry, 
the smaller number of the uninhibited background will 
display. With the same substrate targeting efficacy, p, the 
inhibition efficiency is determined by z, the power of the 
equation component. The inhibitory effect is a power func-
tion concerning the stoichiometry. Thus, the higher the 
stoichiometry, the more efficient the inhibition comparing 
the drugs with same binding affinity. 
The half maximal inhibitory concentration (IC50) is com-
monly used to evaluate drug effect, which quantitatively 
indicates how much of a particular drug is needed to inhibit 
a given biological process by half. Ifwe denote Picso as the 
percentage of drugged subunit needed to reach to 50% 
inhibition in the in vitro assay in the defined system, thus 
l-(1-Picsof=50%. Solving this equation, Picso=l-0.5 112. 
FIG. 17 shows the relationship between stoichiometry (Z) 
and drug targeting level p to reach the inhibition effect (IC), 
where p is the combined result of drug binding efficacy and 
drug concentration (dosage). When biocomplexes with stoi-
chiometry of Z are used as drug targets, the dosage of drug 
or the drug binding affinity presented by percentage of 
is used to package 1.7 bp. As the entire phi29 genomic DNA 
has 19,000 base pairs, it is expected that more than 10000 
ATP molecules are required to package the entire phi29 
genome. Since concerning ATP, the functional unit displayed 35 
in FIG. 5 is the viral production expressed as plaque-forming 
unit (PFU), so the production of one functional unit of PFU 
require 10000 ATP subunits to package one genomic DNA. 
Thus, the ATP in one phi29 nanomotor can be regarded as a 
stoichiometry of 10000. One non-hydrolysable ATP ana- 40 
logue y-S-ATP was treated as the drugged subunit that mixed 
with ATP at different ratios to test the inhibition effect of 
y-S-ATP on phi29 assembly efficiency. It was found that the 
inhibition curve of mutant ATP fits into the theoretical curve 
between Z=l00, K=l and Z=60, K=l (FIG. 16B). The 45 
empirical ATP value derived from binomial distribution 
assay was different from real condition, since the binomial 
distribution equation was based on a condition that each 
subunits has the same binding affinity to the biocomplex in 
the targetednanomotor, but due to the change of the y-S-ATP 50 
structure, it has a ATPase gp16 binding affinity lower than 
the normal ATP. Furthermore, the affinity difference in each 
subunit has a multiplicative effect in the nanomotor's activ-
ity. Thus, there is a big discrepancy between the curves with 
predicted Z value and the empirical Z value. 
Comparing virus assembly inhibition effect using differ-
ent components, the y-S-ATP showed a severe inhibition 
effect (FIG. 16C). Adding 20% of gamma-s-ATP nearly 
completely inhibited the viral assembly. Comparing the 
inhibition effect targeting to ATP, pRNA, ATPase gpl 6, and 60 
DNA with stoichiometry of 10000, 6, 6, and 1, respectively, 
y-S-ATP showed the strongest inhibition effect, while 
drugged mutant pRNA and mutant gp16 showed stronger 
inhibitory effect than mutant DNA (FIG. SC). For example, 
adding 20% mutant DNA caused 20% inhibition effect in 65 
viral assembly, while 20% of drugged mutant pRNA exerted 
74% of inhibition effect on viral assembly and 20% of 
55 drugged subunits to reach IC50, IC25 , or IC75 decreases. This 
clearly shows that as Z increases, decreases (FIG. 17), and 
hence the drug is more potent. 
Discussion 
Aiming to find a method for developing drugs with 
ultra-high potency, we proposed that the inhibition effi-
ciency of a given drug depends on stoichiometry of the 
biocomplex or bio-machine that was used as drug target. 
Here the definition of the stoichiometry is different from 
conventional definition of stoichiometry used to evaluate 
drug efficiency. Conventional thinking in drug development 
emphasizes stoichiometry which refers to the number of 
drug binding per target molecule, which is also known as 
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Bmax· In this study the definition of stoichiometry refers to 
the copy number of subunit within a biocomplex that serves 
as drug target. We used phi29 viral components with a series 
50 
identical to that in human body. For cancers drugs, as long 
as a mutation is found in the multiple-subunit biocomplex, 
it will be an ideal target for potent drug. 
Executive Summary 
Aim 
A method for developing potent drugs is sought. 
Without being bound by theory, drug inhibition potency 
depends on the stoichiometry of the targeted biocomplex. 
Approach: 
Phi29 viral components with variable stoichiometry were 
used as model to prove the hypothesis 
of variable but known stoichiometry as mock drug targets to 
test the hypothesis. Both in vitro and in vivo won assembly 5 
assays were employed to compare the inhibition efficiency 
targeting to components with different numbers of subunit 
stoichiometry. Viral inhibition efficiency was analyzed with 
Yang Hui's (Pascal's) Triangle (or knowns as binomial 
distribution). It was found that inhibition efficiency on virus 10 
replication correlates to the component stoichiometry of 
nano-machine as drug target. It displayed power law inhibi-
tory effect since when K=l, the percentage of uninhibited 
biocomplexes in the population equal to q2 • With the same Virion assembly efficiency was assayed and analyzed with 
15 Yang Hui's Triangle: q and same K value, the inhibition efficiency is determined 
by z, the number of subunits within the biocomplex or the 
bio-machine as drug target. Here z serves as the power in the 
equation, thus, the inhibitory effect is the power of the 
stoichiometry. Empirical data demonstrated that the target 
with thousand-subunits shows higher inhibition effect than 20 
the targets with six subunits, and in turn higher than the 
target with single subunit. 
In evaluation of drug effect, two parameters were com-
monly used. One is the half maximal inhibitory concentra-
tion (IC50), which quantitatively indicates how much of a 25 
particular drug is needed to inhibit a given biological 
process by half. It is universally used as a measure of drug 
potency in pharmacological research. Another important 
parameter is the median lethal dose (LD50), which is also 
known as 50% of lethal concentration (LC50). LD50 is 30 
frequently used to indicate a substance's acute toxicity. 
Obviously, the usefulness of a drug will dependent on the 
ratio of LD50 to IC50 . The larger this ratio, the safer the drug. 
By ways of increasing the inhibition efficiency through 
targeting to the components with high stoichiometry, the 35 
IC50 of a drug will decrease. As a result, lower concentration 
of drug will be required for reaching a desired effect, 
resulting in a reduced toxicity of the drug. 
Results: 
Inhibition efficiency displayed a power function of the 
stoichiometry of the target biocomplexes. The uninhibited 
biocomplex in population can equals to q2 • Thus, the inhibi-
tory effect is a power of the stoichiometry. 
Targets with thousand-subunit showed higher inhibition 
effect than with six subunits, and in tum higher than target 
with single subunit. 
A complete inhibition of virus, bacterium, or cancer was 
demonstrated when targets with high stoichiometry was 
used as target. 
Conclusion: 
Drug inhibition potency depends on the stoichiometry of 
the targeted components of the biocomplex or nano-ma-
chine. 
Most of current anti-cancer, anti-virus or anti-bacteria 
drugs target single enzymes or single proteins. Our data 
showed that drugs selected to target components, biocom-
plexes, or nano-machines with high copy numbers could 
lead to a much higher efficacy, and it could potentially solve 
the problem of low drug effect and multi-drug resistance. 
The inhibition effect displayed a power function of the 
40 stoichiometry of the target biocomplex. 
Conclusions 45 
Targeting the functional biological units with higher stoi-
chiometries will have a higher efficiency of inhibition. The 
inhibition effect is power, other than proportional, and the 
power, is the copy number of the drug-targeted element of 
the machine. The new theory developed herein suggests that 50 
potent drugs can be developed by targeting biocomplex with 
high stoichiometry, and a complete inhibition of virus, 
bacterium, or cancer is possible if a bio-machine with high 
stoichiometry is identified. Since bio-motors share certain 
common structure and operation mechanism in viruses, 55 
bacteria, and cells, approach should have getter-application 
in drug development. 
Future Perspective 
Living systems contain many elegant arrays, motors and 
nanomachines that are multi-subunit complex. As reported 60 
here, these biocomplex with high copy number of compo-
nents can serve as potent drug targets. For example, most 
members of the AAA+ family are hexamer. However, these 
machines are common in living systems therefore the speci-
ficity and toxicity is an issue. For bacteria and virus, since 65 
our goal is to kill them nonexclusively, the specificity and 
toxicity is not an issue as long as the target biocomplex is not 
Since bio-motors share certain common structure and 
operation mechanism in viruses, bacteria, and cells, this 
approach should have general application in drug develop-
ment. 
Finally, for further explanation of the features, benefits 
and advantages of the present invention, attached hereto is 
Appendices A-F, which are incorporated herein by this 
reference in their entirety, as are all cited references in 
Appendices A-F. 
The following two publications (set forth in paragraphs 
00295 and 00296 below) are herein incorporated by refer-
ence in their entirety. 
New approach to develop ultra-high inhibitory drug using 
the power function of the stoichiometry of the targeted 
nanomachine or biocomplex. Publication J and date: Nano-
medicine (Land). 2015 July; 10(12):1881-97. doi: 10.2217/ 
nmn.15.37. 
Discovery of a new method for potent drug development 
using power function of stoichiometry of homomeric bio-
complexes or biological nanomotors. Publication J and date: 
Expert Opin Drug Deliv. 2016 January; 13(1):23-36. 
All publications, patents, and patent applications men-
tioned in this specification, including those set forth in the 
following list, are herein incorporated by reference to the 
same extent as if each individual publication, patent, or 
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patent application was specifically and individually indi-
cated to be incorporated by reference. 
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APPENDIX B 
Tables in this Appendix Correspond to the Tables 
Set Forth in Section 1 
TABLE 1 
58 
Probability of the complex containing M copies of drugged subunits and N copies of undrugged subunits 
Inhibited Z - 3 
Subunits (p) M - 0, N - 3 M -1, N-2 M- 2, N- 1 M - 3, N- 0 
0 1.0000 0.0000 0.0000 0.0000 
0.1 0.7290 0.2430 0.0270 0.0010 
0.2 0.5120 0.3840 0.0960 0.0080 
0.3 0.3430 0.4410 0.1890 0.0270 
0.4 0.2160 0.4320 0.2880 0.0640 
0.5 0.1250 0.3750 0.3750 0.1250 
0.6 0.0640 0.2880 0.4320 0.2160 
0.7 0.0270 0.1890 0.4410 0.3430 
0.8 0.0080 0.0960 0.3840 0.5120 
0.9 0.0010 0.0270 0.2430 0.7290 
0.0000 0.0000 0.0000 1.0000 
Inhibited Z - 12 
Subunits M - 0, M-1, M -2, M- 3, M-4, M - 5, M- 6, M -7, M- 8, M -9, M -10, M -11, 
(p) N-12 N - 11 N-10 N- 9 N- 8 N- 7 N- 6 N- 5 N-4 N-3 N- 2 N-1 
0 1.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
0.1 0.2824 0.3766 0.2301 0.0852 0.0213 0.0038 0.0005 0.0000 0.0000 0.0000 0.0000 0.0000 
0.2 0.0687 0.2062 0.2835 0.2362 0.1329 0.0532 0.0155 0.0033 0.0005 0.0001 0.0000 0.0000 
0.3 0.0138 0.0712 0.1678 0.2397 0.2311 0.1585 0.0792 0.0291 0.0078 0.0015 0.0002 0.0000 
0.4 0.0022 0.0174 0.0639 0.1419 0.2128 0.2270 0.1766 0.1009 0.0420 0.0125 0.0025 0.0003 
0.5 0.0002 0.0029 0.0161 0.0537 0.1208 0.1934 0.2256 0.1934 0.1208 0.0537 0.0161 0.0029 
0.6 0.0000 0.0003 0.0025 0.0125 0.0420 0.1009 0.1766 0.2270 0.2128 0.1419 0.0639 0.0174 
0.7 0.0000 0.0000 0.0002 0.0015 0.0078 0.0291 0.0792 0.1585 0.2311 0.2397 0.1678 0.0712 
0.8 0.0000 0.0000 0.0000 0.0001 0.0005 0.0033 0.0155 0.0532 0.1329 0.2362 0.2835 0.2062 
0.9 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0005 0.0038 0.0213 0.0852 0.2301 0.3766 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
TABLE 2 
Predicted inhibition efficiency of drugs targeting biocomplexes, K - 1 
Drugged Inhibition efficiency of the multi-subunit complex with 
subunit (p) Z-1 Z-2 Z-3 Z-6 Z - 10 Z - 100 Z - 1000 
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
0.1 0.1000 0.1900 0.2710 0.4686 0.6513 1.0000 1.0000 
0.2 0.2000 0.3600 0.4880 0.7379 0.8926 1.0000 1.0000 
0.3 0.3000 0.5100 0.6570 0.8824 0.9718 1.0000 1.0000 
0.4 0.4000 0.6400 0.7840 0.9533 0.9940 1.0000 1.0000 
0.5 0.5000 0.7500 0.8750 0.9844 0.9990 1.0000 1.0000 
0.6 0.6000 0.8400 0.9360 0.9959 0.9999 1.0000 1.0000 
0.7 0.7000 0.9100 0.9730 0.9993 1.0000 1.0000 1.0000 
0.8 0.8000 0.9600 0.9920 0.9999 1.0000 1.0000 1.0000 
0.9 0.9000 0.9900 0.9990 1.0000 1.0000 1.0000 1.0000 
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TABLE 3 
Comparison of proportion of non-inhibited complex between Z - 6 and 
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52*. Gun P. Zhang C, Chen C, Trottier M. Garver K. Inter-I 
interaction of phage phi29 pRNA to form a hexameric 
complex for viral DNA transportation. Mal. Cell. 2, 
149-15, (1998 
1 **. Guo P, Zhao Z, Haak J, Wang S, Weitao T. Common 
Mechanisms of DNA translocation motors in Bacteria and 
Viruses Using One-way Revolution Mechanism without 
Rotation. Biotechnology Advances. 32, 853-872 (2014). 
25 Synopsis: This is the first paper to reveal that the pRNA of 
phi29 DNA packaging motorfirms a hexameric ring, and 
prove-of-concept of RNA nanotechnology since this 
paper shows that by bottom-up assembly, the RNA nan-
Synopsis: This review reports that revolution mechanism is 
commonly used in bacteria and viruses which avoid DNA 
g in translocation the lengthy genomic dsDNA helix. 
30 
19*. Schwartz C, De Donatis GM, F ng H, Guo P. The 
ATPase of the phi29 DNA-packaging motor is a member 35 
of the hexameric AAA+ superfamily. Virology 443, 20-27 
(2013). 
Synopsis: This paper confirmed the stoichiometry of ATPase 
in phi29 motor is a hexamer and provided data suggesting 
that the phi29 motor ATPase belongs to classical hexam- 40 
eric AAA+ superfamily. 
33*. Schwartz C, Donatis GM, Zhang H, Fang H, Guo P. 
Revolution rather than rotation of AAA+ hexameric phi29 
nanomotor for dsDNA packaging without coiling. Virol-
ogy 443, 28-39 (2013). 
Synopsis: This paper shows how the nanomotor in phi29 
virus w with a revolution mechanism using six copies of 
ATPase. 
45 
36**. De-Donatis G, Zhao Z, Wang S et al. Finding of 
50 
widespread viral and bacterial revolution dsDNA trans-
location motors distinct from rotation motors by channel 
chirality and size. Cell & Bioscience 4, 30 (2014). 
Synopsis: This paper reports that the revolution motor 
nanomachine is widespread among biological systems, an 55 
can be distinguished from rotation motors by channel size 
and chirality. 
51 **. Fang H, Huang LP et al. Binomial distribution for 
quantification of protein subunits in biological nanoas-
semblies and functional nanomachines. Nanomedicine. 60 
10(7), 1433-40 (2014). 
Synopsis: This is the first report to describe how to use the 
Yang Hui's Triangle (binomial distribution to determine 
the stoichiometry of protein subunits in biocomplex. It 
precisely confirmed that phi29 motor contains six copies 65 
of ATPase gp16 and one mutant subunit would cause 
motor to stop. 
oparticles of dimers, trimers and hexamers can be con-
structed using the reenginered RNA fragments derived 
from phi29 motor pRNA. 
*56. Trottier M, Quo P. Approaches to determine stoichi-
ometry of viral assembly components. J. Viral. 71, 487-
494 (1997), 
Synopsis: This is the first report to describe how to use the 
Yang Hui Triangle (binomial distribution) to determine 
the stoichiometry of biocomplex or nanomachine. 
81 *. Shu D, Zhang H, Guo P. Counting of six pRNAs of 
phi29 DNA-packaging motor with customized single 
molecule dual-view system. EMBO J. 26, 527-537 
(2007). 
Synopsis: This is the first report describing the use of single 
fluorophore photobleaching technique to count subunits 
in biocomplex, and documents the "seeing is believing" to 
confirm that phi29 DNA packaging motor contains six 
copies of packaging pRNA. 
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APPENDIX E 
Tables in this Appendix Correspond to the Tables 
Set Forth in Paragraphs Section 2 
Z -1 Z - 6 
Inhibited M - 0, M-1, M -0, M-1, M -2, M - 3, M-4, M -5, M- 6, 
Subunits (p) N-1 N-0 N- 6 N- 5 N-4 N- 3 N-2 N-1 N- 0 
0% 100% 0% 100% 0% 0% 0% 0% 0% 0% 
10% 90% 9% 53% 35% 10% 1% 0% 0% 0% 
20% 80% 16% 26% 39% 25% 8% 2% 0% 0% 
30% 70% 21% 12% 30% 32% 19% 6% 1% 0% 
40% 60% 24% 5% 19% 31% 28% 14% 4% 0% 
50% 50% 25% 2% 9% 23% 31% 23% 9% 2% 
60% 40% 24% 0% 4% 14% 28% 31% 19% 5% 
70% 30% 21% 0% 1% 6% 19% 32% 30% 12% 
80% 20% 16% 0% 0% 2% 8% 25% 39% 26% 
90% 10% 9% 0% 0% 0% 1% 10% 35% 53% 
100% 0% 0% 0% 0% 0% 0% 0% 0% 100% 
APPENDIX F 
Tables in this Appendix Correspond to the Tables 25 
Set Forth in Paragraphs Section 3 
TABLE 1 
Inhibited Z-3 Z - 12 
Subunits M - 0, M-1, M -2, M- 3, M- 0, M-1, M- 2, M -3, M-4, 
(p) N- 3 N- 2 N-1 N- 0 N- 12 N- 11 N- 10 N- 9 N- 8 
0 1.0000 0.0000 0.0000 0.0000 1.0000 0.0000 0.0000 0.0000 0.0000 
0.1 0.7290 0.2430 0.0270 0.0010 0.2824 0.3766 0.2301 0.0652 0.0219 
0.2 0.5120 0.3840 0.0960 0.0080 0.0687 0.2062 0.2835 0.2362 0.1329 
0.3 0.3430 0.4410 0.1890 0.0270 0.0138 0.0712 0.1678 0.2397 0.2311 
0.4 0.2160 0.4320 0.2880 0.0640 0.0022 0.0174 0.0619 0.1419 0.2128 
0.5 0.1250 0.3750 0.3750 0.1250 0.0002 0.0029 0.0161 0.0537 0.1208 
0.6 0.0640 0.2880 0.4320 0.2160 0.0000 0.0003 0.0025 0.0125 0.0420 
0.7 0.0270 0.1890 0.4410 0.3430 0.0000 0.0000 0.0002 0.0015 0.0078 
0.8 0.0080 0.0960 0.3540 0.5120 0.0000 0.0000 0.0000 0.0001 0.0005 
0.9 0.0010 0.0270 0.2430 0.7290 0.0000 0.0000 0.0000 0.0000 0.0000 
0.0000 0.0000 0.0000 1.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
Inhibited Z - 12 
Subunits M- 5, M - 6, M- 7, M- 8, M - 9, M - 10, M - 11, M - 12, 
(p) N- 7 N- 6 N- 5 N-4 N- 3 N-2 N-1 N- 0 
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
0.1 0.0038 0.0005 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
0.2 0.0532 0.0155 0.0033 0.0005 0.0001 0.0000 0.0000 0.0000 
0.3 0.1585 0.0792 0.0291 0.0078 0.0015 0.0002 0.0000 0.0000 
0.4 0.2270 0.1766 0.1009 0.0420 0.0125 0.0025 0.0003 0.0000 
0.5 0.1934 0.2256 0.1934 0.1208 0.0537 0.0161 0.0029 0.0002 
0.6 0.1009 0.1766 0.2270 0.2128 0.1419 0.0639 0.0174 0.0022 
0.7 0.0291 0.0792 0.1585 0.2311 0.2397 0.1678 0.0712 0.0138 
0.8 0.0033 0.0155 0.0532 0.1329 0.2362 0.2835 0.2062 0.0687 
0.9 0.0000 0.0005 0.0038 0.0213 0.0832 0.2301 0.3766 0.2524 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 1.0000 
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TABLE 2 
Predicted inhibition efficiency of drugs targeting biocom12lexes: K = 1 
Drugged Inhibition efficiency of the multi-subunit com12lex with 
subunit (p) Z-1 Z-2 Z-3 Z-6 Z - 10 Z - 100 Z - 1000 
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
0.1 0.1000 0.1900 0.2710 0.4686 0.6513 1.0000 1.0000 
0.2 0.2000 0.3600 0.4880 0.7379 0.8926 1.0000 1.0000 
0.3 0.3000 0.5100 0.6570 0.8824 0.9718 1.0000 1.0000 
0.4 0.4000 0.6400 0.7840 0.9533 0.9940 1.0000 1.0000 
0.5 0.5000 0.7500 0.8750 0.9844 0.9990 1.0000 1.0000 
0.6 0.6000 0.8400 0.9360 0.9959 0.9999 1.0000 1.0000 
0.7 0.7000 0.9100 0.9730 0.9993 1.0000 1.0000 1.0000 
0.8 0.8000 0.9600 0.9920 0.9999 1.0000 1.0000 1.0000 
0.9 0.9000 0.9900 0.9990 1.0000 1.0000 1.0000 1.0000 
1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
TABLE 3 
Comparison of proportion of non-inhibited complex between Z - 6 and 
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1. A method for the identification of multi-subunit bio-
complex drug targets, the method comprising, 
identifying a target that performs a biological function, 
wherein the target comprises one or more subunits, 45 
wherein a minimum number (K) of the one or more 
subunits is inactivated (M) to inhibit the biological 
function; 
selecting a drug that binds specifically to each subunit of 
the one or more subunits with a target probability (p), 50 
wherein the target probability comprises a common 
probability for each subunit that the drug delivered to 
the target inactivates the subunit; 
describing a relationship between inhibition efficiency of 
55 
the drug and total number (Z) of the one or more 
subunits using a binomial distribution, wherein the 
inhibition efficiency comprises a probability that the 
delivered drug blocks the biological function, wherein 
the inhibition efficiency is computed with respect to the 
60 
minimum number and the total number; 
confirming empirically the relationship using an experi-
mental target, wherein the target includes the experi-
mental target; 
administering the drug to the target to treat a multi-drug 65 
resistant disease, wherein the target comprises a bio-
logical complex in a mammalian subject. 














2. The method of claim 1, wherein variable N represents 
an active subunit of the one or more subunits, wherein 
Z=M+N. 
3. The method of claim 1, wherein q=l-p. 
4. The method of claim 3, wherein a probability that the 
target includes M inactivated subunits and N active units is 
given by the binomial expression 
(Z!) MN 
(N!)(M!)p q. 
5. The method of claim 4, wherein the inhibition effi-
ciency is given by the binomial equation 
~( Z! ) Mc/'-M U M!(Z-M)! p . 
M=l 
6. The method of claim 5, wherein K=l and Z>l. 
7. The method of claim 6, wherein the inhibition effi-
ciency is given by l-q2 • 
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8. The method of claim 1, wherein the experimental target 
comprises a component or subunit of a multimeric biocom-
plex or a biological nanomotor. 
9. The method of claim 8, wherein the nanomotor com-
prises a linear motor, a rotation motor, or a revolution motor. 5 
10. The method of claim 8, wherein the nanomotor 
comprises an ATPase component. 
11. The method of claim 8, wherein the multimeric 
biocomplex comprises a receptor, a channel, an enzyme, or 
a transporter. 1 o 
12. The method of claim 8, wherein the multimeric 
biocomplex comprises a homomeric biocomplex. 
13. The method of claim 8, wherein the multimeric 
biocomp_lex comprises a dimer, a hetero-oligomer, or a 
homo-ohgomer. 15 
14. The method of claim 8, wherein the number of 
components or subunits is at least 2 3 4 5 6 7 8 9 1 0 
11, or 12. ' ' ' ' ' ' ' ' ' 
15. The method of claim 8, wherein the nanomotor is a 
bacteriophage Phi29 DNA packaging motor. 20 
~6. The method of claim 15, wherein the bacteriophage 
Phi29 DNA packaging motor comprises a genomic dsDNA 
component, a packaging RNA component, an ATPase gp 16 
component, an ATP component, or a combination thereof. 
17. The method of claim 16, wherein each Phi29 DNA 25 
packaging motor component comprises the experimental 
target. 
~8. The method of claim 15, wherein the bacteriophage 
Phi29 DNA packaging motor comprises 1 copy of genomic 
dsDNA, and wherein the copy comprises a subunit. 30 
19. The method of claim 15, wherein the bacteriophage 
Phi29 DNA packaging motor comprises 6 copies of pack-
aging RNA, and wherein the copies comprise subunits. 
20. The method of claim 15, wherein the bacteriophage 
Phi29 DN~ packaging motor comprises 6 copies of gp16, 35 
and wherem the copies comprise subunits. 
~1. The method of claim 15, wherein the bacteriophage 
Phi29 DNA packaging motor comprises 10,000 copies of 
ATP, and wherein the copies comprise subunits. 
~2. The_ meth?d of claim 1, wherein the multi-drug 40 
~es1stant disease 1s caused by a multidrug-resistant organ-
ism. 
23. The method of claim 22, wherein the multidrug-
resistant organism is a bacterium, a fungus, a virus, or a 
parasite. 45 
24. A method for increasing inhibition efficiency of a 
multimeric biocomplex, the method comprising, 
72 
identifyi1;1g a target that performs a biological function, 
wherem the target comprises one or more subunits, 
wherein a minimum number of the one or more sub-
units is inactivated to inhibit the biological function· 
selecting a drug that binds specifically to each subunit ~f 
the one or more subunits with a target probability, 
wherein the target probability comprises a common 
probability for each subunit that the drug delivered to 
the target inactivates the subunit; 
describing a relationship between inhibition efficiency of 
the drug and total number of the one or more subunits 
using a binomial distribution, wherein the inhibition 
efficiency comprises a probability that the delivered 
drug blocks the biological function, wherein the inhi-
bition efficiency is computed with respect to the mini-
mum number and the total number; 
confirming empirically the relationship using an experi-
mental target, wherein the target includes the experi-
mental target; 
administering the drug to the target to treat a multi-drug 
resistant disease, wherein the target comprises a bio-
logical complex in a mammalian subject. 
25. A method for treating a subject afflicted with a 
multi-drug resistant disease, the method comprising, 
identifying a target that performs a biological function, 
wherein the target comprises one or more subunits, 
wherein a minimum number of the one or more sub-
units is inactivated to inhibit the biological function; 
selecting a drug that binds specifically to each subunit of 
the one or more subunits with a target probability, 
wherein the target probability comprises a common 
probability for each subunit that the drug delivered to 
the target inactivates the subunit; 
describing a relationship between inhibition efficiency of 
the drug and total number of the one or more subunits 
using a binomial distribution, wherein the inhibition 
efficiency comprises a probability that the delivered 
drug blocks the biological function, wherein the inhi-
bition efficiency is computed with respect to the mini-
mum number and the total number; 
confirming empirically the relationship using an experi-
mental target, wherein the target includes the experi-
mental target; 
administering the drug to the target to treat a multi-drug 
resistant disease, wherein the target comprises a bio-
logical complex in a mammalian subject. 
* * * * * 
